cluster_labels,Nom du médicament,Substance active,Diseases,A.1 Member State Concerned,A.2 EudraCT number,A.3 Full title of the trial,A.4.1 Sponsor's protocol code number,A.7 Trial is part of a Paediatric Investigation Plan,B.1.1 Name of Sponsor,B.1.3.4	Country,B.3.1 and B.3.2	Status of the sponsor,D.1.2 and D.1.3 IMP Role,D.2.1 IMP to be used in the trial has a marketing authorisation,D.2.1.1.1 Trade name,D.2.1.1.2 Name of the Marketing Authorisation holder,D.2.1.2 Country which granted the Marketing Authorisation,D.2.5 The IMP has been designated in this indication as an orphan drug in the Community,D.3.1 Product name,D.3.10.1 Concentration unit,D.3.10.2 Concentration type,D.3.10.3 Concentration number,D.3.11.1 Active substance of chemical origin,D.3.11.10 Medicinal product containing genetically modified organisms,D.3.11.11 Herbal medicinal product,D.3.11.12 Homeopathic medicinal product,D.3.11.13 Another type of medicinal product,D.3.11.2 Active substance of biological/ biotechnological origin,D.3.11.3 Advanced Therapy IMP,D.3.11.3.1 Somatic cell therapy medicinal product,D.3.11.3.2 Gene therapy medical product,D.3.11.3.3 Tissue Engineered Product,D.3.11.3.4 Combination ATIMP,D.3.11.3.5 Committee on Advanced therapieshas issued a classification for this product,"D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy",D.3.11.5 Radiopharmaceutical medicinal product,D.3.11.6 Immunological medicinal product,D.3.11.7 Plasma derived medicinal product,D.3.11.8 Extractive medicinal product,D.3.11.9 Recombinant medicinal product,D.3.4 Pharmaceutical form,D.3.4.1 Specific paediatric formulation,D.3.8 INN - Proposed INN,D.IMP,E.1.1 Medical conditionbeing investigated,E.1.3 Condition being studied is a rare disease,E.2.1 Main objective of the trial,E.2.2 Secondary objectives of the trial,E.2.3 Trial contains a sub-study,E.3 Principal inclusion criteria,E.4 Principal exclusion criteria,E.5.1 Primary end point,E.6.1 Diagnosis,E.6.10 Pharmacogenetic,E.6.11 Pharmacogenomic,E.6.12 Pharmacoeconomic,E.6.13 Others,E.6.2 Prophylaxis,E.6.3 Therapy,E.6.4 Safety,E.6.5 Efficacy,E.6.6 Pharmacokinetic,E.6.7 Pharmacodynamic,E.6.8 Bioequivalence,E.6.9 Dose response,E.7.1 Human pharmacology,E.7.1.1 First administration to humans,E.7.1.2 Bioequivalence study,E.7.1.3 Other,E.7.2 Therapeutic exploratory,E.7.3 Therapeutic confirmatory,E.7.4 Therapeutic use,E.8.1 Controlled,E.8.1.1 Randomised,E.8.1.2 Open,E.8.1.3 Single blind,E.8.1.4 Double blind,E.8.1.5 Parallel group,E.8.1.6 Cross over,E.8.1.7 Other,E.8.2.1 Other medicinal product,E.8.2.2 Placebo,E.8.2.3 Other,E.8.3 The trial involves single site in the Member State concerned,E.8.4 The trial involves multiple sites in the Member State concerned,E.8.5 The trial involves multiple Member States,E.8.6.1 Trial being conducted both within and outside the EEA,E.8.6.2 Trial being conducted completely outside of the EEA,E.8.7 Trial has a data monitoring committee,E.8.9.1 In the Member State concerned months,E.8.9.1 In the Member State concerned years,F.1.1 Trial has subjects under 18,F.1.1.1 In Utero,F.1.1.2 Preterm newborn infants,F.1.1.3 Newborns,F.1.1.4 Infants and toddlers,F.1.1.5 Children,F.1.1.6 Adolescents,F.1.2 Adults,F.1.3 Elderly,F.2.1 Female,F.2.2 Male,F.3.1 Healthy volunteers,F.3.2 Patients,F.3.3 Specific vulnerable populations,F.3.3.2 Women of child-bearing potential using contraception,F.3.3.3 Pregnant women,F.3.3.4 Nursing women,F.3.3.5 Emergency situation,F.3.3.6 Subjects incapable of giving consent personally,F.3.3.7 Others,F.4.1 In the member state,F.4.2.1 In the EEA,F.4.2.2 In the whole clinical trial,N. Competent Authority Decision,N. Date of Competent Authority Decision,N. Date of Ethics Committee Opinion,N. Ethics Committee Opinion,N. Ethics Committee Opinion of the trial application,P. End of Trial Status
3,Pegasys,peginterferon alfa-2a,"['compensée signes réplication', 'inflammation', 'aghbe positif chez enfants non cirrhotiques adolescents', 'prise cas cas voir rubrique 4 4']",Italy - Italian Medicines Agency,2006-000977-31,"PHASE IIIB, RANDOMIZED, OPEN LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR",NV25361,Yes,F. HOFFMANN - LA ROCHE LTD.,Switzerland,Commercial,Test,Yes,Lamivudine,TEVA Pharma B.V,United Kingdom,No,Pegasys,mg milligram(s),equal,100,Yes,No,No,No,No,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,No,No,Film-coated tablet,No,LAMIVUDINA,3,Chronic Hepatitis B Virus infection in children.,No,"To evaluate the efficacy of Pegasys¿ + lamivudine compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.","¿To evaluate efficacy of Pegasys¿ + lamivudine compared with an untreated control in children with CHB, as measured by seroconversion to anti-HBs, seroconversion to anti-HBe, loss of HBeAg, and HBV DNA levels, at 24 weeks post-end of treatment/end of untreated observation",No,• Male and female patients 3 to less than 18 years of age at baseline (12– 17 years of age at baseline in Russia),"Patients who have had any previous anti-HBV treatment, or who are co-infected with hepatitis A virus (HAV), HCV, hepatitis D virus (HDV) or HIV, or who have decompensated liver disease will be excluded.",The primary efficacy endpoint is defined as loss of HBsAg at 24 weeks post-end of treatment (follow-up Week 24)/end of untreated observation (Week 80).,No,No,No,No,No,No,Yes,Yes,Yes,Yes,Yes,No,No,No,No,No,No,No,Yes,No,Yes,Yes,Yes,No,No,Yes,No,No,No,No,Yes,No,Yes,Yes,Yes,Information not present in EudraCT,Yes,0,7,Yes,No,No,No,No,Yes,Yes,No,No,Yes,Yes,No,Yes,Yes,Yes,No,No,No,Yes,No,4,57,114,Authorised,2015-08-10,,Reason(s) for unfavourable opinion:,,Completed
2,Karvezide,"irbesartan, hydrochlorothiazide","['hypertension', 'hypertension']",Belgium - FPS Health-DGM,2004-000020-32,The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line,CV131-176,Information not present in EudraCT,Bristol Myers Squibb International Corporation,Belgium,Commercial,Test,Information not present in EudraCT,Karvezide,"Bristol Myers Squibb Pharma EEIG, 141-149 Staines Road, Hounslow, TW3 3JA, UK",Belgium,No,Karvezide,mg milligram(s),equal,12.5,Yes,No,No,No,No,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Tablet,Information not present in EudraCT,Hydrochlorothiazide,2,Severe Hypertension,No,"The primary objective of this study is to compare the proportion of subjects whose seated diastolic blood pressure (SeDBP) is controlled (SeDBP < 90mmHg) at Week 5 when initiating irbesartan 150mg/HCTZ 12.5mg combination therapy as first-line treatment (titrated to irbesartan 300mg/HCTZ 25mg), as compared to initiating irbesartan 150mg monotherapy and titrating to irbesartan 300mg.","To characterize the safety/tolerability in the two treatment groups over the sevenweek study period, examining in particular the frequency of treatment",Information not present in EudraCT,* Subjects must have uncontrolled hypertension defined as:,* SeSBP ≥ 220mmHg or SeDBP ≥ 130mmHg and/or evidence of malignant or,The primary efficacy outcome measurements is the proportion of subjects with seated diastolic blood pressure less than 90 mmHg at the end of Week 5.,No,Information not present in EudraCT,No,No,No,No,Yes,Yes,Yes,No,No,No,No,No,No,No,No,No,Yes,No,Yes,Yes,No,No,Yes,Yes,No,No,Yes,No,No,No,Yes,Yes,Yes,Information not present in EudraCT,Information not present in EudraCT,8,,No,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,Yes,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,No,36,254,826,Authorised,2005-02-16,2004-12-21,Reason(s) for unfavourable opinion:,Favourable,Completed
1,Norvir,ritonavir,['infections'],Spain - AEMPS,2008-001611-38,Estudio piloto prospectivo de la farmacocinética y farmacodinamia de la interaciión entre tipranavir/ritonavir y raltegravir en pacientes infectados por el VIH-1,PK12-RAL/TPV,Information not present in EudraCT,Jose M Gatell - Hospital Clinic de Barcelona,Spain,Non-Commercial,Test,Yes,Norvir,Abbot Laboratories Ltd,Spain,No,Norvir,mg milligram(s),equal,100,Yes,No,No,No,No,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Information not present in EudraCT,"Capsule, soft",Information not present in EudraCT,ritonavir,3,Pacientes con infección crónica por VIH-1,No,Evaluar la interacción farmacocinética entre raltegravir y la combinación de tipranavir/ritonavir en pacientes VIH que reciben ambos fármacos en una pauta de rescate.,Evaluación de la respuesta virológica e inmunológica a las 24 semanas,No,Pacientes con infección por VIH,"Embarazo, lactancia o previsión de embarazo durante el periodo de estudio","Comparación de los niveles plasmáticos de raltegravir administrado sin TPV/r ( basal : día 5) y tras su administración conjunta con TPV/r (tras alcanzado el equilibrio estacionario (steady state) de éste a partir de las dos semanas de su coadministración, aproximadamente en el día 20)",No,No,No,No,No,No,No,Yes,No,Yes,Yes,No,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Yes,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,No,No,Information not present in EudraCT,No,,1,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,Yes,Yes,No,Yes,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,10,,,Authorised,2008-06-27,2008-05-23,Reason(s) for unfavourable opinion:,Favourable,Ongoing
3,Bonviva,ibandronic acid,"['fractures', 'fractures']",Sweden - MPA,2009-014414-98,The impact of local bisphosphonate treatment on prosthetic fixation,58185,Information not present in EudraCT,Department of Orthopaedic Surgery University Hospital Linköping,Sweden,Non-Commercial,Test,Yes,Bonviva,,Sweden,No,Bonviva,mg/ml milligram(s)/millilitre,equal,3mg to 3ml,Yes,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Spot-on solution,Information not present in EudraCT,,1,Osteoarthritis of the hip joint treated with total hip replacement,No,To Investigate if local treatment of the bonebed with bisphosphonate solution prior to fixation of the acetabular component of a cemented hip prosthesis decreases the risk for future loosening of the prosthesis.,,Information not present in EudraCT,Patients 50-65 years of age with primary osteoarthritis of the hip that are planned  for total hip arthroplasty.,"Osteoporosis. Treatment with coticosteroids. Treatment with drugs that influence bone metabolism e.g.bisphosphonates, cytostatic drugs, anticonvulsive drugs.",Local treatment of the acetabular bone bed with bisphosphonate drugs results in less resorption of the periprosthetic bone and consequently in a more stabile fixation.,No,No,No,No,No,Yes,No,No,No,No,No,No,No,No,No,No,Yes,Yes,No,No,Yes,Yes,Information not present in EudraCT,Information not present in EudraCT,Yes,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Information not present in EudraCT,Yes,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,6,1,No,No,No,No,No,No,No,Yes,No,Yes,Yes,No,Yes,No,No,No,No,No,No,No,60,,,Authorised,2009-10-29,2009-10-14,Reason(s) for unfavourable opinion:,Favourable,Completed
3,Ruconest,Recombinant human C1-inhibitor,['déficit inhibiteur'],Germany - PEI,2011-000987-92,"Open-label, phase II, single arm study to evaluate the safety, immunogenicity, pharmacokinetics and efficacy of recombinant human C1 inhibitor for the treatment of acute attacks in pediatric patients with hereditary angioedema, from 2 up to and including 13 years of age",C11209,Yes,Pharming Technologies B.V.,Netherlands,Commercial,Test,Yes,Ruconest,Pharming Group N.V,European Union,No,Ruconest,U unit(s),range,50 U / kg BW to 4200,No,No,No,No,No,Yes,No,No,No,No,No,No,No,No,No,No,No,Yes,Powder for solution for injection,No,CONESTAT ALFA,1,Attacks associated with hereditary angioedema (HAE) in pediatric population 2-13 years of age.,Yes,"To assess the clinical safety, immunogenicity and tolerability of Ruconest in the treatment of acute angioedema attacks in 2-13 year old HAE patients.",To assess the pharmacokinetics (PK) and pharmacodynamics (PD) of Ruconest in the treatment of acute angioedema attacks in 2-13 year old HAE patients.,No,Screening,Screening,Assessment of safety and tolerability.,No,No,No,No,No,No,Yes,Yes,Yes,Yes,Yes,No,No,No,No,No,No,Yes,No,No,No,No,Yes,No,No,No,No,No,No,No,No,No,Yes,Yes,Yes,No,No,1,3,Yes,No,No,No,No,Yes,Yes,No,No,Yes,Yes,No,Yes,Yes,No,No,No,No,Yes,No,6,14,20,Authorised,2011-09-26,2011-08-02,Reason(s) for unfavourable opinion:,Favourable,Completed
3,Ruconest,Recombinant human C1-inhibitor,['déficit inhibiteur'],Czech Republic - SUKL,2011-000987-92,"Open-label, phase II, single arm study to evaluate the safety, immunogenicity, pharmacokinetics and efficacy of recombinant human C1 inhibitor for the treatment of acute attacks in pediatric patients with hereditary angioedema, from 2 up to and including 13 years of age",C11209,Yes,Pharming Technologies B.V.,Netherlands,Commercial,Test,Yes,Ruconest,Pharming Group N.V,Netherlands,No,Ruconest,U unit(s),range,50 U/kg BW-4200 U,No,No,No,No,No,Yes,No,No,No,No,No,No,No,No,No,No,No,Yes,Powder for solution for injection,No,CONESTAT ALFA,1,Attacks associated with hereditary angioedema (HAE) in pediatric population 2-13 years of age.,Yes,"To assess the clinical safety, immunogenicity and tolerability of Ruconest in the treatment of acute angioedema attacks in 2-13 year old HAE patients.",To assess the pharmacokinetics (PK) and pharmacodynamics (PD) of Ruconest in the treatment of acute angioedema attacks in 2-13 year old HAE patients.,No,Screening,Screening,Assessment of safety and tolerability.,No,No,No,No,No,No,Yes,Yes,Yes,Yes,Yes,No,No,No,No,No,No,Yes,No,No,No,No,Yes,No,No,No,No,No,No,No,No,No,Yes,Yes,Yes,No,No,5,0,Yes,No,No,No,No,Yes,Yes,No,No,Yes,Yes,No,Yes,Yes,No,No,No,No,Yes,No,6,30,40,Authorised,2014-08-29,2014-10-02,Reason(s) for unfavourable opinion:,Favourable,Completed
3,Ruconest,Recombinant human C1-inhibitor,['déficit inhibiteur'],Slovakia - SIDC (Slovak),2011-000987-92,"Open-label, phase II, single arm study to evaluate the safety, immunogenicity, pharmacokinetics and efficacy of recombinant human C1 inhibitor for the treatment of acute attacks in pediatric patients with hereditary angioedema, from 2 up to and including 13 years of age",C11209,Yes,Pharming Technologies B.V.,Netherlands,Commercial,Test,Yes,Ruconest,Pharming Group N.V,Netherlands,No,Ruconest,U unit(s),range,50 U/kg BW-4200 U,No,No,No,No,No,Yes,No,No,No,No,No,No,No,No,No,No,No,Yes,Powder for solution for injection,No,CONESTAT ALFA,1,Attacks associated with hereditary angioedema (HAE) in pediatric population 2-13 years of age.,Yes,"To assess the clinical safety, immunogenicity and tolerability of Ruconest in the treatment of acute angioedema attacks in 2-13 year old HAE patients.",To assess the pharmacokinetics (PK) and pharmacodynamics (PD) of Ruconest in the treatment of acute angioedema attacks in 2-13 year old HAE patients.,No,Screening,Screening,Assessment of safety and tolerability.,No,No,No,No,No,No,Yes,Yes,Yes,Yes,Yes,No,No,No,No,No,No,Yes,No,No,No,No,Yes,No,No,No,No,No,No,No,No,No,Yes,Yes,Yes,No,No,5,0,Yes,No,No,No,No,Yes,Yes,No,No,Yes,Yes,No,Yes,Yes,No,No,No,No,Yes,No,6,30,40,Authorised,2014-09-24,2014-09-24,Reason(s) for unfavourable opinion:,Favourable,Completed
3,Ruconest,Recombinant human C1-inhibitor,['déficit inhibiteur'],Hungary - National Institute of Pharmacy,2011-000987-92,"Open-label, phase II, single arm study to evaluate the safety, immunogenicity, pharmacokinetics and efficacy of recombinant human C1 inhibitor for the treatment of acute attacks in pediatric patients with hereditary angioedema, from 2 up to and including 13 years of age",C11209,Yes,Pharming Technologies B.V.,Netherlands,Commercial,Test,Yes,Ruconest,Pharming Group N.V,European Union,No,Ruconest,U/ml unit(s)/millilitre,equal,150,No,No,No,No,No,Yes,No,No,No,No,No,No,No,No,No,No,No,Yes,Powder for solution for injection,No,CONESTAT ALFA,1,Attacks associated with hereditary angioedema (HAE) in pediatric population 2-13 years of age.,Yes,"To assess the clinical safety, immunogenicity and tolerability of Ruconest in the treatment of acute angioedema attacks in 2-13 year old HAE patients.",To assess the pharmacokinetics (PK) and pharmacodynamics (PD) of Ruconest in the treatment of acute angioedema attacks in 2-13 year old HAE patients.,No,Screening,Screening,Assessment of safety and tolerability.,No,No,No,No,No,No,Yes,Yes,Yes,Yes,Yes,No,No,No,No,No,No,Yes,No,No,No,No,Yes,No,No,No,No,No,No,No,No,No,Yes,Yes,Yes,No,No,9,0,Yes,No,No,No,No,Yes,Yes,No,No,Yes,Yes,No,Yes,Yes,No,No,No,No,Yes,No,2,20,20,Authorised,2015-09-14,2015-09-07,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Janumet,"sitagliptin, metformin hydrochloride",['complément régime alimentaire exercices physiques améliorer contrôle glycémique chez patients insuffisamment contrôlés dose maximale tolérée'],Germany - BfArM,2011-000518-21,Cross-over study to assess the difference in fasting plasma glucose (FPG) between vildagliptin (Galvus®/Eucreas®) and sitagliptin (Januvia®/Janumet®) after two weeks (FPG-VISIT),CLMF237ADE02,No,Novartis Pharma GmbH,Germany,Commercial,Comparator,Yes,Janumet,"Merck Sharp & Dohme, Inc.",European Union,No,Janumet,mg milligram(s),equal,1000,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,Film-coated tablet,No,METFORMIN HYDROCHLORIDE,2,Diabetes mellitus type 2,No,To assess the difference in FPG between vildagliptin and sitagliptin after two weeks in patients with type 2 diabetes mellitus pre-treated with metformin.,To assess the difference in FPG between vildagliptin and sitagliptin after a missed dose of either drug in patients with type 2 diabetes mellitus on concomitant treatment with metformin.,No,1.	Type 2 diabetic patients stabilized on metformin monotherapy (stable dose for at least 4 weeks prior to Screening) ≥ 1000 mg/day and ≤ 2000 mg/day.,1.	FPG ≥ 270mg/dL (15mmol/L) at Visit 1 and Visit 102.,The primary objective of the study is to demonstrate that the FPG after 14 days of treatment with Vildagliptin is superior to the FPG after 14 days of treatment with.,No,No,No,No,No,No,Yes,Yes,Yes,No,No,No,No,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,No,No,Yes,No,Yes,No,No,No,Yes,No,No,No,No,0,1,No,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,No,No,No,No,100,,,Authorised,2011-04-29,2011-06-20,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Retacrit,epoetin zeta,['rapporté événements thromboemboliques traitement doit être administré'],Sweden - MPA,2011-001673-70,EPO to protect renal function after cardiac surgery. EPRICS. A phase II double blind randomized controlled study.,,No,Skånes Universitetssjukhus,Sweden,Non-Commercial,Test,Yes,Retacrit,Hospira UK Limited,United Kingdom,No,Retacrit,,,,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,Injection,No,,1,Renal function after cardiac surgery,No,To study the efficacy of erythropoietin zeta with brand name Retracrit® given preoperatively in Coronary Artery Bypass Grafting (CABG) patients to attenuate further decrease in renal dysfunction after open heart surgery and it’s safety. Different biological markers for kidney function will be measured postoperatively.,Secondary objectives will be regarding to the study drugs potential effect on brain and heart. These will be evaluated by specific biomarkers.,No,Patients planed for Coronary Artery Bypass Grafting (CABG).,"Exclusion criteria: Uncontrolled hypertension, pregnancy or fertile woman (less than 50 years old), Epo treatment within 4 weeks, eGFR-CyC<15 or dialysis, known malignancy and Off-pump surgery",Primary endpoint: Plasma CyC change from day -1 to day 3.,No,No,No,No,No,Yes,No,No,Yes,No,No,No,No,No,No,No,No,Yes,No,No,Yes,Yes,No,No,Yes,Yes,No,No,No,Yes,No,Yes,No,No,No,No,No,5,,No,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,Yes,No,No,No,No,No,No,No,70,,,Authorised,2011-07-27,2011-08-09,Reason(s) for unfavourable opinion:,Favourable,Completed
3,Sifrol,pramipexole dihydrochloride monohydrate,"['parkinson idiopathique seul sans lévodopa association lévodopa est-à-dire cours évolution maladie jusqu stades avancés lorsque effet lévodopa', 'sifrol indiqué', 'traitement symptomatique syndrome jambes sans repos idiopathique modéré sévère']",Germany - BfArM,2005-003788-22,"A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson’s disease patients with stable motor function and depressive symptoms.",248.596,Information not present in EudraCT,Boehringer Ingelheim Pharma GmbH & Co. KG,Germany,Commercial,Test,Yes,Sifrol,Boehringer Ingelheim International GmbH,European Union,No,Sifrol,mg milligram(s),equal,0.7,Yes,No,No,No,No,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Information not present in EudraCT,Tablet,Information not present in EudraCT,Pramipexole,4,"A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson’s disease patients with stable motor function and depressive symptoms",No,"To investigate the efficacy of pramipexole, compared with placebo in treating Parkinson’s  disease patients with stable motor function and depressive symptoms.  The efficacy of pramipexole vs. placebo will be based on the Beck Depression Inventory (BDI) total score.","To assess further depression response (% patients with 50% reduction from baseline in total BDI score, GDS total score, and UPDRS part I), motor function (standard version UPDRS part II & III), complications of therapy (UPDRS part IV), anhedonia (SHAPS), quality of life (PDQ-39 and EQ-5D), Clinical Global Improvement (CGI-I) and pain (VAS)",Information not present in EudraCT,1. 15-item Geriatric Depression Scale (GDS)  ≥ 5,"1. Previous history of allergic response, lack of efficacy or complications with pramipexole or its excipients.","The primary endpoint for this study is clinical response after 12 weeks of treatment, defined as a change in total score of baseline symptoms as measured by the BDI total score.",No,No,No,No,No,No,No,Yes,Yes,No,No,No,No,No,No,No,No,No,No,Yes,Yes,Yes,No,No,Yes,Yes,No,No,No,Yes,No,No,Yes,Yes,Yes,Information not present in EudraCT,Information not present in EudraCT,12,,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,No,No,No,No,40,248,354,Authorised,2005-12-05,2006-02-01,Reason(s) for unfavourable opinion:,Favourable,Completed
3,Mirapexin,pramipexole dihydrochloride monohydrate,"['parkinson idiopathique seul sans lévodopa association lévodopa est-à-dire cours évolution maladie jusqu stades avancés lorsque effet lévodopa', 'traitement symptomatique syndrome jambes sans repos idiopathique modéré sévère']",Hungary - National Institute of Pharmacy,2007-006271-37,Dopamin agonista pramipexol hatása tinnitusra presbyacusisban,MIRA 1/2007,Information not present in EudraCT,"Medical and Health Science Center, University of Debrecen Dept. of Otolaryngology",Hungary,Non-Commercial,Test,Information not present in EudraCT,MIRAPEXIN,Boehringer Ingelheim,Hungary,No,Mirapexin,,,,Yes,No,No,No,Information not present in EudraCT,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Information not present in EudraCT,Tablet,Information not present in EudraCT,,1,Tinnitus and old age presbycusis.,No,To study the putative efficacy of Mirapexin on tinnitus and presbycusis.,,No,"Age over 50 years,",Conductive hearing loss,Hearing after 4 weeks and 12 weeks after one month treatment.,No,No,No,No,No,No,Yes,No,Yes,No,No,No,No,No,No,No,No,Yes,No,No,Yes,Yes,No,No,Yes,Yes,No,No,No,Yes,No,Yes,No,No,No,Information not present in EudraCT,No,1,,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,Yes,Yes,No,Yes,No,No,No,No,No,No,No,40,40,40,Authorised,2008-06-16,2008-02-06,Reason(s) for unfavourable opinion:,Favourable,Ongoing
0,NutropinAq,somatropin,"['turner nanisme hypophyse traitement long terme enfants présentant retard', 'turner traitement enfants prépubères présentant retard croissance associé', 'croissance origine infantile adulte déficit hormone croissance doit']",Denmark - DHMA,2004-000356-17,"PHASE IIIB, INTERNATIONAL, SINGLE GROUP, OPEN STUDY TO DEFINE AN OPTIMAL MONITORING OF IGF-I IN CHILDREN TREATED WITH NUTROPINAQ",2-79-58035-700,Information not present in EudraCT,Beaufour Ipsen Pharma,France,Commercial,Test,Information not present in EudraCT,NutropinAq,Ipsen Ltd,Denmark,No,NutropinAq,mg/ml milligram(s)/millilitre,equal,,No,No,No,No,No,Yes,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Solution for injection,Information not present in EudraCT,Somatropin,1,"Children presenting growth failure associated with Growth Hormone Deficiency (GHD), Tuner Syndrome (TS) or Chronic Renal Insufficiency (CRI).",No,The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients,The factors affecting the variability of capillary IGF-I measurements; i.e. to establish whether the variability of IGF-I levels is homogeneously distributed in the patient population and/or if individual factors affect the day to day variability of IGF-I levels.,Information not present in EudraCT,Children (boys and girls under 18) with growth failure associated with:,Children with hypersensitivity to somatropin or any of the excipients,The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients,No,Information not present in EudraCT,No,No,Yes,No,Yes,Yes,Yes,No,No,No,No,No,No,No,No,No,No,Yes,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Yes,Yes,No,Information not present in EudraCT,Information not present in EudraCT,6,1,Yes,No,No,No,No,Yes,Yes,No,No,Yes,Yes,No,Yes,Information not present in EudraCT,Information not present in EudraCT,No,No,No,Yes,No,6,250,250,Authorised,2004-12-15,2005-04-19,Reason(s) for unfavourable opinion:,Favourable,Completed
0,NutropinAq,somatropin,"['turner nanisme hypophyse traitement long terme enfants présentant retard', 'turner traitement enfants prépubères présentant retard croissance associé', 'croissance origine infantile adulte déficit hormone croissance doit']",Austria - BASG,2004-000356-17,"Phase IIIB, international, single group, open study to define an optimal monitor-ing of IGF-I in children treated with NutropinAq™, using a novel capillary blood collection method",2-79-58035-700,Information not present in EudraCT,Beaufour Ipsen Pharma,France,Commercial,Test,Information not present in EudraCT,NutropinAq,"Ipsen Ltd., UK",Austria,No,NutropinAq,mg/ml milligram(s)/millilitre,equal,5,No,No,No,No,Yes,Yes,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Solution for injection,Information not present in EudraCT,Somatropin,1,"Children presenting growth failure associated with Growth Hormone Deficiency (GHD), Tuner Syndrome (TS) or Chronic Renal Insufficiency (CRI).",No,The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients.,The factors affecting the variability of capillary IGF-I measurements; i.e. to establish whether the variability of IGF-I levels is homogeneously distributed in the patient population and/or if individual factors affect the day to day variability of IGF-I levels.,Information not present in EudraCT,Children (boys and girls under 18) with growth failure associated with:,Children with hypersensitivity to somatropin or any of the excipients,The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients,No,Information not present in EudraCT,No,No,Yes,No,Yes,Yes,Yes,No,No,No,No,No,No,No,No,No,No,Yes,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Yes,Yes,No,Information not present in EudraCT,Information not present in EudraCT,6,1,Yes,No,No,No,No,Yes,Yes,No,No,Yes,Yes,No,Yes,Information not present in EudraCT,Information not present in EudraCT,No,No,No,Yes,No,5,250,250,Authorised,2005-03-12,2005-03-12,Reason(s) for unfavourable opinion:,Favourable,Completed
0,NutropinAq,somatropin,"['turner nanisme hypophyse traitement long terme enfants présentant retard', 'turner traitement enfants prépubères présentant retard croissance associé', 'croissance origine infantile adulte déficit hormone croissance doit']",Sweden - MPA,2004-000356-17,"PHASE IIIB, INTERNATIONAL, SINGLE GROUP, OPEN STUDY TO DEFINE AN OPTIMAL MONITORING OF IGF-I IN CHILDREN TREATED WITH NUTROPINAQ",2-79-58035-700,Information not present in EudraCT,Ipsen Scandinavia,Denmark,Commercial,Test,Information not present in EudraCT,NutropinAq,Ipsen Ltd,Sweden,No,NutropinAq,,,,No,No,No,No,No,Yes,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Solution for injection,Information not present in EudraCT,,1,"Children presenting growth failure associated with Growth Hormone Deficiency (GHD), Tuner Syndrome (TS) or Chronic Renal Insufficiency (CRI).",No,The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients,Secundary objectives,Information not present in EudraCT,Children (boys and girls under 18) with growth failure associated with:,Children with hypersensitivity to somatropin or any of the excipients,The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients,No,Information not present in EudraCT,No,No,Yes,No,Yes,Yes,Yes,No,No,No,No,No,No,No,No,No,No,Yes,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,No,Information not present in EudraCT,Information not present in EudraCT,6,1,Yes,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,No,Yes,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,6,250,250,Authorised,2005-08-29,,Reason(s) for unfavourable opinion:,,Completed
0,NutropinAq,somatropin,"['turner nanisme hypophyse traitement long terme enfants présentant retard', 'turner traitement enfants prépubères présentant retard croissance associé', 'croissance origine infantile adulte déficit hormone croissance doit']",Finland - Fimea,2004-000356-17,"PHASE IIIB, INTERNATIONAL, SINGLE GROUP, OPEN STUDY TO DEFINE AN OPTIMAL MONITORING OF IGF-I IN CHILDREN TREATED WITH NUTROPINAQ",2-79-58035-700,Information not present in EudraCT,Ipsen Scandinavia,Denmark,Commercial,Test,Information not present in EudraCT,NutropinAq,Ipsen Ltd,Finland,No,NutropinAq,,,,No,No,No,No,No,Yes,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Solution for injection,Information not present in EudraCT,,1,"Children presenting growth failure associated with Growth Hormone Deficiency (GHD), Tuner Syndrome (TS) or Chronic Renal Insufficiency (CRI).",No,The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients,Secundary objectives,Information not present in EudraCT,Children (boys and girls under 18) with growth failure associated with:,Children with hypersensitivity to somatropin or any of the excipients,The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients,No,Information not present in EudraCT,No,No,Yes,No,Yes,Yes,Yes,No,No,No,No,No,No,No,No,No,No,Yes,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,No,Information not present in EudraCT,Information not present in EudraCT,6,1,Yes,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,No,Yes,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,15,250,250,Authorised,2006-04-25,2006-05-16,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Iressa,gefitinib,"['adultes atteints cancer poumon', 'récepteur facteur croissance']",Austria - BASG,2004-005093-24,"Multicentre, open label, extension study of treatment with gefitinib (IRESSA™) for patients completing other gefitinib clinical studies who may benefit from gefitinib treatment",D791AC00008,Information not present in EudraCT,AstraZeneca Österreich GmbH,Austria,Commercial,Test,Information not present in EudraCT,,,,No,Iressa,mg milligram(s),equal,250,Yes,No,No,No,No,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Tablet,Information not present in EudraCT,gefitinib,1,This trial is for patients with advanced non-small cell lung cancer who have completed a preceding gefitinib trial (ZD1839IL0709 or ZD1839IL0710) and in the opinion of the investigator may benefit from gefitinib treatment,Information not present in EudraCT,"The primary objective of this study is to provide, or continue to provide, gefitinib treatment to patients who have recently participated in other gefitinib clinical studies.",There are no secondary objectives of the study.,Information not present in EudraCT,1.Provision of informed consent,1.Known severe hypersensitivity to gefitinib or any of the excipients of this product,There are no endpoints for this study,No,Information not present in EudraCT,No,No,Yes,No,No,No,No,No,No,No,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,Yes,Yes,Yes,Information not present in EudraCT,Information not present in EudraCT,,,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,Yes,Yes,No,Yes,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,No,6,176,533,Authorised,2005-01-24,2005-01-24,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Iressa,gefitinib,"['adultes atteints cancer poumon', 'récepteur facteur croissance']",Hungary - National Institute of Pharmacy,2004-005093-24,"Multicentre, open label, extension study of treatment with gefitinib (IRESSA™) for patients completing other gefitinib clinical studies who may benefit from gefitinib treatment",D791AC00008,Information not present in EudraCT,AstraZeneca AB,Sweden,Commercial,Test,Information not present in EudraCT,,,,No,Iressa,mg milligram(s),equal,250,Yes,No,No,No,No,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Tablet,Information not present in EudraCT,gefitinib,1,This trial is for patients with advanced non-small cell lung cancer who have completed a preceding gefitinib trial (ZD1839IL0709 or ZD1839IL0710) and in the opinion of the investigator may benefit from gefitinib treatment,Information not present in EudraCT,"The primary objective of this study is to provide, or continue to provide, gefitinib treatment to patients who have recently participated in other gefitinib clinical studies.",There are no secondary objectives of the study.,Information not present in EudraCT,1.Provision of informed consent,1.Known severe hypersensitivity to gefitinib or any of the excipients of this product,There are no endpoints for this study,No,Information not present in EudraCT,No,No,Yes,No,No,No,No,No,No,No,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,Yes,Yes,Yes,Information not present in EudraCT,Information not present in EudraCT,,,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,Yes,Yes,No,Yes,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,No,,176,533,Authorised,2004-12-20,2004-12-10,Reason(s) for unfavourable opinion:,Favourable,Ongoing
0,Iressa,gefitinib,"['adultes atteints cancer poumon', 'récepteur facteur croissance']",Latvia - SAM,2004-005093-24,"Multicentre, open label, extension study of treatment with gefitinib (IRESSA) for patients completing other gefitinib clinical studies who may benefit from gefitinib treatment",D791AC00008,Information not present in EudraCT,AstraZeneca AB,Sweden,Commercial,Test,Information not present in EudraCT,,,,No,Iressa,mg milligram(s),equal,250,Yes,No,No,No,No,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,,Information not present in EudraCT,gefitinib,1,This trial is for patients with advanced non-small cell lung cancer who have completed a preceding gefitinib trial (ZD1839IL0709 or ZD1839IL0710) and in the opinion of the investigator may benefit from gefitinib treatment,Information not present in EudraCT,"The primary objective of this study is to provide, or continue to provide, gefitinib treatment to patients who have recently participated in other gefitinib clinical studies.",There are no secondary objectives of the study.,Information not present in EudraCT,1.Provision of informed consent,1.Known severe hypersensitivity to gefitinib or any of the excipients of this product,There are no endpoints for this study,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,Yes,No,Yes,Yes,No,No,No,No,No,No,No,No,No,No,Yes,Yes,Yes,Information not present in EudraCT,Information not present in EudraCT,,,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,Yes,Yes,No,Yes,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,No,2,176,533,Authorised,2005-01-28,2004-12-10,Reason(s) for unfavourable opinion:,Favourable,Completed
3,Zydelig,Idelalisib,"['aucun autre traitement', 'adultes atteints lymphome folliculaire fl', 'réfractaire deux lignes traitement']",UK - MHRA,2012-003631-36,CALiBRe: Assessment of the Mechanism of Action of idelalisib (CAL-101) in B-cell Receptor Pathway Inhibition in CLL,RG_12-124,No,University of Birmingham,United Kingdom,Non-Commercial,Test,Yes,Zydelig,Gilead Sciences International,United Kingdom,Yes,Zydelig,mg milligram(s),equal,100 to 150,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,Tablet,No,"Idelalisib formerly CAL-101, GS-1101",1,Chronic lymphocytic leukaemia,Yes,To investigate the mechanism of action of idelalisib,To assess the biological response to idelalisib,Yes,1. Chronic lymphocytic leukaemia requiring therapy,1. Previously untreated for CLL,•Proportion of patients achieving MRD-negative remission by IWCLL criteria (depletion of CLL below 0.01% in the peripheral blood and bone marrow),No,No,No,No,No,No,No,Yes,Yes,No,Yes,No,No,No,No,No,No,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,Yes,No,No,No,Yes,11,4,No,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,Yes,No,No,No,No,No,No,No,40,,0,Authorised,2015-02-10,2015-01-22,Reason(s) for unfavourable opinion:,Favourable,GB - no longer in EU/EEA
0,Temodal,temozolomide,['atteints gliome malin tel'],Sweden - MPA,2004-002925-39,A Phase II study of Temozolomide (Temodal) Given Continously 100mg/m2 for 21 Days in 28 Day cycles in Patients with Metastatic Melanoma.,040826,Information not present in EudraCT,"Kliniken för onkologi, Karolinska Universitetssjukhuset, Solna",Sweden,Non-Commercial,Test,Information not present in EudraCT,Temodal,Schering-Plough Europe,Sweden,No,Temodal,mg milligram(s),,250,Yes,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,"Capsule, hard",Information not present in EudraCT,Temozolomide,6,Metastatic melanoma,No,To investigate the efficacy and safety of Temodal in a continuous dose regime in patients with metastatic melanoma and good performance status defined as WHO 0-2.,"Time to progression, Overall survival, Safety, new brain metastasis, correlation of response to tumor gene and MGMT expression and SNPs, Temodal  effect on Regulatory T lymphocytes.",Information not present in EudraCT,Histologically proven melanoma,"Prior chemotherapy, biologic therapy or immunotherapy for metastatic disease",Tumor respons rate,No,Information not present in EudraCT,No,No,No,No,Yes,Yes,Yes,No,No,No,No,No,No,No,No,Yes,No,No,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,Yes,No,No,No,Information not present in EudraCT,Information not present in EudraCT,,2,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,Yes,Yes,No,Yes,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,No,35,0,35,Authorised,2005-02-02,2005-01-26,Reason(s) for unfavourable opinion:,Favourable,Ongoing
3,Myozyme,alglucosidase alfa,['tardive preuves'],Netherlands - Competent Authority,2007-001375-11,Effects and health economic aspects of enzyme therapy in children and adults with Pompe disease,not applicable,Information not present in EudraCT,,,,Test,Yes,Myozyme,Genzyme,Netherlands,No,Myozyme,,,,No,Yes,No,No,No,Yes,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Information not present in EudraCT,Intravenous infusion,Information not present in EudraCT,,1,"Pompe disease (glycogen storage disease type II) is a genetic, lysosomal storage disorder with a frequency of 1 in 40.000 newborns. The disease is caused by deficiency of alpha-glucosidase, a lysosomal hydrolase involved in the degradation of glycogen.",Yes,"The objective of the study is to gather more information about the long-term effect of enzyme therapy in patients with Pompe disease with a different severity of disease. The goal is also to set guideline for start and stop of treatment and to evaluate health economic aspects. Furthermore, it is important to find an optimal dosing regimen.",not applicable,No,"1. Patients should have a proven diagnosis of Pompe disease, which means that the diagnosis is confirmed by deficiency of a-glucosidase activity in leukocytes or skeletal muscle, or by a documented mutation in the a-glucosidase gene.",Patients who are not likely to benefit from treatment,-	Survival,Yes,Information not present in EudraCT,Information not present in EudraCT,Yes,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,No,No,Yes,No,No,No,No,No,No,No,No,No,No,No,Yes,No,No,No,Information not present in EudraCT,No,,3,Yes,No,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,No,Yes,No,100,,,Authorised,2007-04-10,2007-05-16,Reason(s) for unfavourable opinion:,Favourable,Ongoing
0,Circadin,melatonin,"['troubles ’ initiation maintien sommeil', 'insomnie primaire caractérisée mauvaise qualité sommeil chez']",UK - MHRA,2009-014388-38,"A double-blind, parallel group, randomized, placebo controlled study of  the efficacy of Circadin® 2mg in alleviating sleep disturbances in patients with mild to moderate Alzheimer Disease (AD) treated with Acetylcholinesterase (AChE) inhibitor.",NEUAZ1,Information not present in EudraCT,Neurim Pharmaceuticals Ltd,Israel,Commercial,Test,Yes,Circadin 2mg,RAD Neurim Pharmaceuticals EEC Ltd,European Union,No,Circadin,mg milligram(s),equal,2,Yes,No,No,No,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Information not present in EudraCT,Prolonged-release tablet,Information not present in EudraCT,Melatonin,1,Insomnia in patients with mild to moderate Alzheimers Disease.,No,"To compare the effect of Circadin® to that of placebo, on sleep quality as assessed by the Daily Sleep Diary after 12 weeks of the double-blind treatment period.","- To compare the effect of Circadin® to that of placebo onCognitive parameters,",No,"1) Suffering from sleep disturbances, characterized by poor sleep quality",1)	Severe agitation.,"The effect of Circadin to that of placebo, on sleep quality as assessed by the Daily Sleep Diary after 12 weeks of double-blind treatment.",No,No,No,No,No,No,Yes,Yes,Yes,No,No,No,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,No,Yes,Yes,No,Yes,Yes,Yes,No,No,No,Yes,No,No,Yes,No,Yes,Information not present in EudraCT,No,3,1,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,Yes,Yes,No,Yes,Yes,No,No,No,No,Yes,No,60,60,210,Authorised,2009-09-02,2009-09-28,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Tarceva,erlotinib,"['cancer poumon', 'indiqué traitement entretien substitution chez', 'cancer poumon', 'cancer poumon', 'cancer pancréas tarceva']",UK - MHRA,2005-004508-35,THE USE OF PET/CT SCANNING TO ASSESS EARLY RESPONDERS TO TARCEVA (ERLOTINIB): A PHASE II STUDY,2680,Information not present in EudraCT,Royal Marsden Hospital,United Kingdom,Non-Commercial,Test,Information not present in EudraCT,Tarceva,Roche,United Kingdom,No,Tarceva,,,,Yes,No,No,No,No,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Coated tablet,Information not present in EudraCT,,1,Advanced non-small cell lung cancer (NSCLC),No,To assess whether using PET/CT scans at baseline and at 6 weeks will be more predictive of response to Tarceva than standard scanning methods in patients with NSCLC.,"To correlate radiological response with symptomatic response, duration of treatment and survival.",Information not present in EudraCT,1.	Histologically confirmed diagnosis of stage IIIB/IV NSCLC overexpressing EGFR (i.e ≥10% membrane staining on tumour cells via Dako IHC kit).,1. 	Any concurrent anticancer cytostatic or cytotoxic chemotherapy.,1.	Document early response or progression in patients after 6 weeks of erlotinib by PET/CT scanning.,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Information not present in EudraCT,Yes,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,No,No,No,No,No,No,No,Yes,No,No,No,Information not present in EudraCT,Information not present in EudraCT,,2,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,Yes,Yes,No,Yes,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,No,35,,,Authorised,2005-11-22,2005-12-14,Reason(s) for unfavourable opinion:,Favourable,Completed
3,Votrient,pazopanib,['traitement cytokines maladie avancée sarcome tissus mous sts votrient indiqué traitement patients adultes atteints sous-types sélectifs sarcome'],Spain - AEMPS,2011-002441-34,"Ensayo clínico fase II, abierto, no controlado y multicéntrico de pazopanib en monoterapia para determinar la eficacia y la seguridad en segunda línea de tratamiento en pacientes con carcinoma de células renales (CCR) avanzado que han progresado o que no han tolerado una primera línea de tratamiento con un inhibidor de la tirosina quinasa (TKI)",APRO02-2011,No,Associació Per la Recerca Oncològica (APRO),Spain,Non-Commercial,Test,Yes,Votrient 400 mg comprimidos recubiertos con película,GLAXO GROUP LTD.,Spain,No,Votrient,mg milligram(s),equal,800,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,Tablet,No,PAZOPANIB HIDROCLORURO,1,Carcinoma de células renales avanzado.,No,Determinar la tasa de respuestas objetivas (TRO) que ofrece el tratamiento de segunda línea con pazopanib en pacientes con carcinoma de células renales (CCR) avanzado que han progresado o que no han tolerado una primera línea de tratamiento con un TKI.,Determinar para estos pacientes en tratamiento con pazopanib de segunda línea:,Yes,1.	Los pacientes deberán otorgar su consentimiento por escrito para la participación en el estudio antes de la realización de cualquier procedimiento asociado al estudio y deberán mostrarse dispuestos a cumplir con el tratamiento y el seguimiento.,1.	Neoplasia previa. Podrán incluirse en el estudio pacientes que presenten un intervalo libre de enfermedad de 5 años en el momento de la inclusión en el estudio y los pacientes con carcinoma de piel no melanoma completamente resecado o de carcinoma in situ tratado con éxito.,Objetivo principal: Determinar la tasa de respuestas objetivas (TRO) que ofrece el tratamiento de segunda línea con pazopanib en pacientes con carcinoma de células renales (CCR) avanzado que han progresado o que no han tolerado una primera línea de tratamiento con un TKI,No,Yes,No,No,No,No,No,Yes,Yes,No,No,No,No,No,No,No,No,Yes,No,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,Yes,No,No,No,No,6,2,No,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,Yes,No,No,No,No,No,No,No,27,,,Authorised,2012-01-18,2011-12-14,Reason(s) for unfavourable opinion:,Favourable,Completed
3,Tyverb,lapatinib,"['tumeurs sein tyverb', 'traitement patientes atteintes cancer sein', 'capécitabine chez patientes atteintes maladie', 'inhibiteur ’ aromatase aucune donnée disponible efficacité cette']",Germany - BfArM,2012-000598-22,"Randomised, open-label phase II study to compare the safety and efficacy of lapatinib plus trastuzumab or lapatinib plus capecitabine in trastuzumab-resistant HER2-overexpressing metastatic breast cancer",BNGO/01,No,Berufsverband der niedergelassenen gynäkologischen Onkologen in Deutschland e.V.; BNGO e.V.,Germany,Non-Commercial,Comparator,Yes,Xeloda,Roche Registration Lmited,Germany,No,Tyverb,,,,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,Film-coated tablet,No,,4,Trastuzumab-resistant HER2-overexpressing metastatic breast cancer,No,Estimate the clinical benefit of lapatinib plus trastuzumab compared to lapatinib plus capecitabine as measured by investigator-assessed progression-free survival (PFS),•	Evaluate overall survival of lapatinib plus trastuzumab relative to lapatinib plus capecitabine,No,"	Women with histologically confirmed breast cancer; measurable metastatic disease; HER2-positive (IHC 3+ or ISH positive); Hormone receptor-negative; prior treatment with trastuzumab, anthracycline and taxanes; progression on trastuzumab as first-line or second-line therapy; no prior treatment with lapatinib within last 6 months; Adequate hematologic, renal and liver function; normal cardiac function with LVEF of ≥50%; ECOG performance status 0-1; No evidence of brain metastases (asymptomatic metastases that have been clinically stable for 3 months are allowed); no significant cardiovascular disease or other serious medical condition; written informed consent to participate in the trial and to the donation of formalin fixed, paraffin embedded tumour sample from the primary or recurrent cancer available for central testing.",•	1. Patients with confirmed brain metastases or a history of primary central nervous system tumours or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases. Patients with treated brain metastases that are asymptomatic and have been clinically stable for 3 months will be eligible for protocol participation.,"The 6-month PFS-rate (PFS6) will be the number of patients without disease progression or death within 6 months from the date of randomization, divided by the number of patients in the respective analysis population. For the purpose of the analysis patients who are lost to follow-up or deceased in at or before 6 months after randomization will be counted as “disease progression”.",No,No,No,No,No,No,Yes,Yes,Yes,No,No,No,Yes,No,No,No,No,Yes,No,No,Yes,Yes,Yes,No,No,No,No,No,Yes,No,No,No,Yes,No,No,No,Yes,,,No,No,No,No,No,No,No,Yes,No,Yes,No,No,Yes,No,No,No,No,No,No,No,100,,,Authorised,2013-03-08,2013-03-18,Reason(s) for unfavourable opinion:,Favourable,Prematurely Ended
0,Axura,memantine hydrochloride,['atteints maladie alzheimer'],UK - MHRA,2010-020737-50,"Prospective, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of 10mg memantine in the treatment of memory, concentration or attention problems (subjective cognitive impairment) in the absence of dementia",MRZ90001_2267_1,Information not present in EudraCT,Merz Pharmaceuticals GmbH,Germany,Commercial,Test,Yes,Axura,Merz Pharmaceutical GmbH,United Kingdom,No,Axura,mg milligram(s),equal,10,Yes,No,No,No,No,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Information not present in EudraCT,Film-coated tablet,Information not present in EudraCT,memantine hydrochloride,1,"Subjective memory, concentration or attention problems (subjective cognitive impairment) in the absence of dementia",No,"The primary objective of this study is to investigate the efficacy and safety of 10mg/day memantine in comparison to placebo in the treatment of memory, concentration or attention problems (subjective cognitive impairment) in the absence of dementia.","To investigate the efficacy of 10mg memantine in comparison to placebo measured by the CogState computer-based neuropsychological test battery [C-NTB], Everyday Cognition 39 [ECog 39], and Hospital Anxiety and Depression Scale [HADS]",No,"1. Written informed consent obtained from the subject,","1. Memory, concentration or attention problems interfere with basic daily activities,  2. Significant neurological disease or major psychiatric disorder (e.g. diagnosis of psychosis or dementia).","The primary efficacy endpoint is defined as “Patient Global Impression of Change” (PGI-C) at visit 4. The primary efficacy analysis is the statistical comparison between the placebo group and the memantine group at Visit 4 in the Full Analysis Set [FAS] where missing values will be imputed using the Last observation carried forward [LOCF] approach. The group comparison will be performed by the use of an analysis of covariance (ANCOVA) model, with treatment group, “Patient Global Impression Severity” (PGI-S) at screening, gender, age, education, and pooled center as factors. Additionally a reduced ANCOVA model with treatment group and pooled centers as factors will be used. To consider a possible violation of the assumptions of the non-parametric test a Cochan-Mantel-Haenszel test with modified ridit scores stratified by pooled centers will be performed. Furthermore a responder analysis using a logistic regression model will be performed with treatment group, PGI-S at screening, gender, age, education, and pooled centre as independent variables as well as a reduced responder analysis using treatment group and pooled center as independent variables. Response is defined as any improvement in the Subject Global Assessment of Change. Additionally summary statistics will be provided for raw values and the change to Visit 4. Sensitivity analyses of the results will be based on the FAS using observed cases, on the PPS using LOCF and on the PPS using observed cases.",No,No,No,No,No,No,Yes,Yes,Yes,No,No,No,No,No,No,No,No,Yes,No,No,Yes,Yes,No,No,Yes,Yes,No,No,No,Yes,No,No,Yes,Yes,No,Information not present in EudraCT,No,8,,No,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,No,No,No,No,150,300,300,Authorised,2010-09-17,2010-11-10,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Axura,memantine hydrochloride,['atteints maladie alzheimer'],Germany - BfArM,2010-020737-50,"Prospective, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of 10mg memantine in the treatment of memory, concentration or attention problems (subjective cognitive impairment) in the absence of dementia",MRZ90001_2267_1,Information not present in EudraCT,Merz Pharmaceuticals GmbH,Germany,Commercial,Test,Yes,Axura,Merz Pharmaceutical GmbH,European Union,No,Axura,mg milligram(s),equal,10,Yes,No,No,No,No,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Information not present in EudraCT,Film-coated tablet,Information not present in EudraCT,memantine hydrochloride,1,"Subjective memory, concentration or attention problems (subjective cognitive impairment) in the absence of dementia",No,"The primary objective of this study is to investigate the efficacy and safety of 10mg/day memantine in comparison to placebo in the treatment of memory, concentration or attention problems (subjective cognitive impairment) in the absence of dementia.","To investigate the efficacy of 10mg memantine in comparison to placebo measured by the CogState computer-based neuropsychological test battery [C-NTB], Everyday Cognition 39 [ECog 39], and Hospital Anxiety and Depression Scale [HADS]",No,"1. Written informed consent obtained from the subject, 2. Understanding of study procedures and willingness to abide by all procedures during the course of the study, 3. Age ≥50 and ≤80, 4. Subjective worsening of memory, concentration or attention problems for longer than 6 months, 5. Woman of childbearing potential  must be using a highly effective method of birth control, 6. Subject can confirm that a relative or friend has noticed the memory, concentration or attention problems of the subject, 7.“Patient Global Impression Severity” (PGI-S) score of ≥3, 8. Experience of the memory, concentration or attention problems at least four times per week, 9. MiniCog score of 3 or more","1. Memory, concentration or attention problems interfere with basic daily activities,","The primary efficacy endpoint is defined as “Patient Global Impression of Change” (PGI-C) at visit 4. The primary efficacy analysis is the statistical comparison between the placebo group and the memantine group at Visit 4 in the Full Analysis Set [FAS] where missing values will be imputed using the Last observation carried forward [LOCF] approach. The group comparison will be performed by the use of an analysis of covariance (ANCOVA) model, with treatment group, “Patient Global Impression Severity” (PGI-S) at screening, gender, age, education, and pooled center as factors. Additionally a reduced ANCOVA model with treatment group and pooled centers as factors will be used. To consider a possible violation of the assumptions of the non-parametric test a Cochan-Mantel-Haenszel test with modified ridit scores stratified by pooled centers will be performed. Furthermore a responder analysis using a logistic regression model will be performed with treatment group, PGI-S at screening, gender, age, education, and pooled centre as independent variables as well as a reduced responder analysis using treatment group and pooled center as independent variables. Response is defined as any improvement in the Subject Global Assessment of Change. Additionally summary statistics will be provided for raw values and the change to Visit 4.",No,No,No,No,No,No,Yes,Yes,Yes,No,No,No,No,No,No,No,No,Yes,No,No,Yes,Yes,No,No,Yes,Yes,No,No,No,Yes,No,No,Yes,Yes,No,Information not present in EudraCT,No,8,0,No,No,No,No,No,No,No,Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,No,No,No,No,No,150,300,300,Authorised,2010-09-21,2010-10-21,Reason(s) for unfavourable opinion:,Favourable,Completed
1,Viramune,nevirapine,"['infections', 'jours']",Italy - Italian Medicines Agency,2016-002413-22,"Open label, Randomized (1:1), clinical trial to evaluate switching from dual regimens based on Dolutegravir plus a reverse transcriptase inhibitor to  elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in virologically suppressed, HIV-1 infected patients.",Be-OnE1/08-03-2016,No,OSPEDALE SAN RAFFAELE,Italy,Non-Commercial,Comparator,Yes,VIRAMUNE - 400 MG - COMPRESSA A RILASCIO PROLUNGATO - USO ORALE - BLISTER (PVC/AL) 30 COMPRESSE,BOEHRINGER INGELHEIM INTERNATIONAL GMBH,Italy,No,Viramune,mg milligram(s),equal,400,Yes,No,No,No,No,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,No,No,Prolonged-release tablet,No,NEVIRAPINA,10,HIV infection,No,To investigate Residual Viremia  through 48 weeks in virologically suppressed patients randomized to continue treatment with Dolutegravir plus a single RTI or to switch to E/C/F/TAF.,Secondary Objectives,No,1.	Age >18  years,1.	Active AIDS-defining condition (except Kaposi’s sarcoma non requiring systemic chemotherapy),Proportion of subjects without Residual Viremia  through 48 weeks of follow-up.,No,No,No,No,Yes,No,Yes,Yes,Yes,No,Yes,No,No,No,No,No,Yes,No,Yes,No,Yes,Yes,Yes,No,No,Yes,No,No,Yes,No,No,Yes,No,No,No,Information not present in EudraCT,No,24,2,No,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,Yes,No,No,No,No,No,No,No,100,100,100,Authorised,2016-10-31,2016-07-14,Reason(s) for unfavourable opinion:,Favourable,Prematurely Ended
2,INOmax,Nitric oxide,"['hypertension', 'hypertension', 'hypertension', 'afin diminuer sélectivement poumons pression']",Sweden - MPA,2008-006776-29,NO som behandling vid knäproteskirurgi.,081016,Information not present in EudraCT,Karolinska Institutet,Sweden,Non-Commercial,Test,Yes,INOmax,INO Therapeutics (IKARIA),Sweden,No,INOmax,,,,No,No,No,No,Yes,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Information not present in EudraCT,,Information not present in EudraCT,,1,Patienter som skall genomgå knäprotesoperation och skall ha bedövning i form av ryggbedövning (spinalanestes/epiduralanestesi).,No,"Att undersöka om NO (nitric oxide, kväveoxid) kan modulerar det inflammatoriska svar som sker vid sk. reperfusionsskada.",,No,Patienter som planeras genomgå elektiv knäprotesoperation pga leddestruktion. Anestesival skall vara ryggbedövning (spinal och eller epidural).,Pat med handikappande hjärtsvikt.,Inflammaationsmarkörer i blod och muskel.,No,No,No,No,No,Yes,No,No,No,No,No,No,No,No,No,No,Yes,Yes,No,No,Yes,Yes,No,No,Yes,Yes,No,Yes,Information not present in EudraCT,Yes,Information not present in EudraCT,Yes,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,,1,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,No,No,No,No,45,,,Authorised,2009-02-18,2008-12-17,Reason(s) for unfavourable opinion:,Favourable,Ongoing
0,Cetrotide,cetrorelix (as acetate),['humaine'],UK - MHRA,2009-012847-40,A Randomised Study Comparing Two Different Regimens of Ovarian Stimulation Using Pergoveris and Cetrorelix for Controlled Ovarian Superovulation in Assisted Conception Treatment.,Pergoveris_Cetrorelix_1,Information not present in EudraCT,The University of Edinburgh,United Kingdom,Non-Commercial,Test,Yes,Cetrotide,Serono Europe Ltd,European Union,No,Cetrotide,mg milligram(s),equal,0.25,Yes,No,No,No,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Information not present in EudraCT,Injection*,Information not present in EudraCT,Cetrorelix,2,Subfertility,No,"The aim of this study is to investigate whether controlled ovarian stimulation using Pergoveris with early administration of Cetrorelix (from day 2 of period, i.e. day 1 of gonadotrophin stimulation) versus administration of cetrorelix starting on day 6 of stimulation will result in more top quality embryos.",- Number and size of follicles on day of hCG.,No,-	healthy female;,-	polycystic ovarian syndrome,number of top quality embryos resulted from the treatment cycle,No,No,No,No,No,No,Yes,No,Yes,No,No,No,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Yes,Yes,Yes,Yes,No,No,No,No,No,No,No,Yes,Yes,No,No,No,Information not present in EudraCT,No,18,,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,Yes,No,No,Yes,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,80,80,80,Authorised,2009-11-11,2009-08-18,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Thyrogen,thyrotropin alfa,"['cancer thyroïde bien différencié', 'maintenus sous traitement', 'risque thyroïde bien différenciée carcinome taux sériques tg indétectables thst aucune augmentation taux tg stimulée tsh rh', 'humaine', 'cancer thyroïde bien différencié', 'signes cancer']",Austria - BASG,2006-004980-79,Effect of the short –term thyrotropin increase after administration of Recombinant Human Thyrotropin on T lymphocyte cytokine production pattern and bone metabolism in healthy subjects,001,Information not present in EudraCT,Medical University of Vienna,Austria,Non-Commercial,Test,Yes,Thyrogen,genzyme,Netherlands,No,Thyrogen,,,,No,No,No,No,Information not present in EudraCT,Yes,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,Yes,Information not present in EudraCT,Powder for injection*,Information not present in EudraCT,,1,This is a healthy volunteers trial. Thyrogen is used in patients with thyroid cancer.,No,The main objective of the trial is the effect of recombinant human thyrotropin in bone metabolism and its correlation to the potential changes in the T-lymphocyte cytokine production pattern in healthy volunteers.,,No,Men and women without evidence of thyroid disease. Age between 20-45.,"Prior or present history of thyroid disease. Pregnancy or nursing. Significant cardiac, renal, pulmonary or hepatic disease. Recent surgery or trauma. Malnutrition. Ingestion of medications known to affect the thyroid function. Alcohol or drug dependence. Previous administration of rhTSH.",,No,No,No,No,No,No,No,No,No,No,Yes,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,No,Yes,Yes,No,No,Yes,No,Yes,Information not present in EudraCT,No,Yes,No,Yes,No,No,No,Information not present in EudraCT,No,0,1,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,Yes,Yes,Yes,No,Yes,Yes,No,No,No,No,No,20,,,Authorised,2006-10-10,2006-10-10,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Puregon,follitropin beta,['anovulation compris syndrome ovaires polykystiques sopk chez femmes'],Denmark - DHMA,2005-002679-34,The effect of LH priming in early follicular phase on the endocrinological function of the ovary and pregnancy rate in GnRh downregulated women stimulated by exogen gonadotophins in IVF-treatment,1-2005,Information not present in EudraCT,"The Fertility Clinic, Sygehus Viborg (Skive)",Denmark,Non-Commercial,Comparator,Information not present in EudraCT,Puregon cylinderampul 300IE,Organon,Denmark,No,Puregon,IU international unit(s),up to,,No,No,No,No,No,Yes,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Injection*,Information not present in EudraCT,Follitrophin beta,3,Infertility,No,Estimate of the effect of LH-priming in early follicular phase after 3 different stimulations regimes in IVF-treatment.,"Comparism of follicles, oocyte quality and pregnancty rate.",Information not present in EudraCT,Women aged 18- 38 years in IVF-treatment,Male infertility with low sperm count necessitating microinsemination for fertilization,Serum oestradiol on the day of hCG administration,No,Information not present in EudraCT,No,No,No,No,Yes,No,Yes,No,No,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,Yes,No,Yes,No,No,No,No,Yes,No,No,Yes,No,No,No,Information not present in EudraCT,Information not present in EudraCT,,1,No,No,No,No,No,No,No,No,No,Yes,Information not present in EudraCT,Information not present in EudraCT,Yes,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Information not present in EudraCT,150,150,150,Authorised,2005-11-02,2005-11-02,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Eucreas,"vildagliptin, metformin hydrochloride",['complément régime alimentaire exercices physiques améliorer contrôle glycémique chez adultes atteints diabète sucré type 2 chez'],Germany - BfArM,2011-003818-16,"A randomized, open-label, cross-over study to evaluate patient preferences for Eucreas® versus Victoza® as add-on to Metformin in Type 2 Diabetes mellitus patients who did not have adequate glycaemic control with metformin",CLMF237ADE03,No,Novartis Pharma GmbH,Germany,Commercial,Comparator,No,Metformin Stada,Stadapharm GmbH,Germany,No,Eucreas,mg milligram(s),equal,1000,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,Film-coated tablet,No,METFORMIN HYDROCHLORIDE,3,type 2 diabetes mellitus,No,The primary objective of this trial is to demonstrate that a higher proportion of subjects with T2DM and inadequate glycemic control have a preference for an oral treatment with the SPC of vildagliptin/metformin compared to an injectable treatment with liraglutide as add-on to metformin after experiencing both treatments.,•	To evaluate the subjective reason of preference for an oral or and injectable treatment after experiencing both treatments.,No,1. Age: > 18 and < 80 years at Visit 1.,1.	FPG ≥270mg/dL (15.0 mmol/L) at Visit 1.,The primary outcome variable is the patient´s preference for one treatment.,No,No,No,No,No,No,Yes,Yes,Yes,No,No,No,No,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,No,No,Yes,No,Yes,No,No,No,Yes,No,No,No,No,6,1,No,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,No,No,No,No,60,,,Authorised,2011-12-21,2011-11-21,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Mimpara,cinacalcet hydrochloride,['tels définis directives thérapeutiques pertinentes'],Sweden - MPA,2012-005374-57,Primary hyperparathyroidism: Short-term calcimimetics treatment – Relevance for parathyroid surgery decisions?,Calcimimetics,No,"Department of Breast and Endocrine Surgery, Karolinska University Hospital",Sweden,Non-Commercial,Test,Yes,Mimpara,Amgen Europe B.V.,Sweden,No,Mimpara,mg/g milligram(s)/gram,not less then,30 to 120,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,Tablet,No,CINACALCET,1,"Primary hyperparathyroidism (PHPT) is a common disease, characterized by a high-normal calcium concentration and an inappropriately increased parathyroid hormone (PTH) level",No,To determine the relevance of short-term calcimimetics treatment in primary hyperparathyroidism for decision of parathyroid surgery,•To assess the feasibility of the study design,No,"•Primary hyperparathyroidism, scheduled for parathyroid surgery",•Pregnancy,•If four weeks of treatment with Mimpara will normalize hypercalcemia in patients with PHPT,No,No,No,No,No,No,Yes,Yes,Yes,No,No,No,No,No,No,No,No,No,Yes,No,Yes,Yes,Yes,No,No,Yes,No,No,No,No,Yes,Yes,No,No,No,No,No,,2,No,No,No,No,No,No,No,Yes,No,Yes,No,No,Yes,No,Yes,No,No,No,No,No,100,,,Authorised,2013-02-15,2013-02-13,Reason(s) for unfavourable opinion:,Favourable,Ongoing
0,Taxotere,docetaxel,"['ganglions positifs cancer sein opérable sans ganglions négatifs patientes atteintes cancer sein opérable sans ganglions négatifs traitement', 'traitement primaire cancer sein', 'traitement patientes atteintes cancer sein localement', 'cancer sein localement', 'capécitabine indiqué traitement patientes atteintes cancer sein localement avancé métastatique après échec', 'cancer poumon', 'cancer poumon', 'cancer prostate']",Spain - AEMPS,2005-001499-10,'Pilot trial of Pegilated Liposomal Doxorrubicin (Caelyx) in combination with Docetaxel (Taxotere) in advanced breast cancer patients',CO34,Information not present in EudraCT,Dr. José Ramón Mel Lorenzo,Spain,,Test,Information not present in EudraCT,Taxotere,AVENTIS PHARMA S.A.,Spain,No,Taxotere,mg milligram(s),equal,20.,Yes,No,No,No,Yes,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Solution for infusion,Information not present in EudraCT,DOCETAXEL,2,Advanced Breast Cancer,No,To value efficiency of Caelyx (30mg/m2) in combination with Docetaxel (60mg/m2) in a pilot trial administrated in 3 weeks-cicles during 6 cicles in advanced breast cancer patients,To value segurity and tolerance of the combination Pegilated Liposomal Doxorubicin (Caelyx) and Docetaxel (Taxotere) as teraphy in advanced breast cancer,Information not present in EudraCT,Aged > 18 years,No cardiopathy history,Overall response rate,No,Information not present in EudraCT,No,No,No,No,Yes,Yes,Yes,No,No,No,No,No,No,No,No,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,Yes,No,No,Information not present in EudraCT,Information not present in EudraCT,40,,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,Yes,No,No,Yes,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,No,30,,,Authorised,2005-05-19,2004-12-10,Reason(s) for unfavourable opinion:,Favourable,Ongoing
0,Herceptin,trastuzumab,"['tumeurs estomac', 'sein cancer', 'également avoir échoué traitement hormonal sauf si', 'cancer sein', 'atteintes cancer sein', 'traitement']",Germany - PEI,2007-000348-28,"A single arm, multi-centre, international, continuation trial of recombinant humanized antibody Herceptin® (trastuzumab) in patients with HER2 overexpressing tumors.",BO15943,Information not present in EudraCT,F. Hoffmann-La Roche Ltd,Switzerland,Commercial,Test,Yes,Herceptin®,Roche Registration Limited,European Union,No,Herceptin,mg milligram(s),equal,150,No,No,No,No,Yes,Yes,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Information not present in EudraCT,Powder for concentrate for solution for infusion,Information not present in EudraCT,Trastuzumab,1,To continue to provide treatment to those patients that may still be on treatment at the moment of the final data base closure/clinical cut-off of a clinical trials in which Herceptin® is investigated and that further benefit from treatment with Herceptin®.,No,To provide long term follow-up and safety data in patients receiving Herceptin® following completion of a global Roche sponsored Herceptin® trial.,,No,1. Signed informed consent,1. Pregnant or nursing women; women of childbearing potential unless using effective contraception as determined by the investigator.,• To provide Herceptin® to patients with HER2 overexpressing disease following completion of any global Roche sponsored Herceptin® study.,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Information not present in EudraCT,Information not present in EudraCT,Yes,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,Yes,Yes,Yes,Information not present in EudraCT,No,,,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,No,No,No,No,6,22,30,Authorised,2007-08-14,2007-08-30,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Herceptin,trastuzumab,"['tumeurs estomac', 'sein cancer', 'également avoir échoué traitement hormonal sauf si', 'cancer sein', 'atteintes cancer sein', 'traitement']",Portugal - INFARMED,2007-000348-28,"A single arm, multi-centre, international, continuation trial of recombinant humanized antibody Herceptin® (trastuzumab) in patients with HER2 overexpressing tumors.",BO15943,Information not present in EudraCT,F. Hoffman-La Roche Ltd,Switzerland,Commercial,Test,Yes,Herceptin®,Roche Registration Limited,European Union,No,Herceptin,mg milligram(s),equal,150,No,No,No,No,Yes,Yes,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Information not present in EudraCT,Powder for concentrate for solution for infusion,Information not present in EudraCT,Trastuzumab,1,To continue to provide treatment to those patients that may still be on treatment at the moment of the final data base closure/clinical cut-off of a clinical trials in which Herceptin® is investigated and that further benefit from treatment with Herceptin®.,No,To provide long term follow-up and safety data in patients receiving Herceptin® following completion of a global Roche sponsored Herceptin® trial.,,No,1. Signed informed consent,1. Pregnant or nursing women; women of childbearing potential unless using effective contraception as determined by the investigator.,• To provide Herceptin® to patients with HER2 overexpressing disease following completion of any global Roche sponsored Herceptin® study.,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Information not present in EudraCT,Information not present in EudraCT,Yes,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,Yes,Yes,Information not present in EudraCT,No,,,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,No,No,No,Information not present in EudraCT,1,22,30,Authorised,2007-08-20,2007-11-09,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Avastin,bevacizumab,"['côlon rectum bevacizumab', 'récepteur 2 facteur croissance', 'humain', 'capécitabine indiqué', 'comme', 'adultes atteints cancer poumon', 'adultes atteints cancer poumon', 'récepteur facteur croissance', 'adultes atteints cancer', 'adultes atteints cancer', 'cancer']",Austria - BASG,2008-008852-18,Profile of soluble and cellular biomarkers and of functional imaging during antiangiogenic therapies in cancer patients,PRAEMARKERAAT08,Information not present in EudraCT,Medizinische Universität Innsbruck Innere Medizin V,Austria,Non-Commercial,,Yes,Avastin,Roche,Germany,No,Avastin,,,,No,No,No,No,No,Yes,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,Yes,No,No,Information not present in EudraCT,Concentrate and solvent for solution for injection,Information not present in EudraCT,Bevacizumab,3,"The present project is an academic clinical trial in which patient suffering from hepatocellular carcinoma, non-small cell lung cancer, renal cell cancer and colorectal cancer treated routinely with antiangiogenic agents. The study protocol intends to include ten patients per tumour entitity (n=40), treated either with Sorafenib (Nexavar), Bevacizumab (Avastin) or Sunitinib (Sutent), which are all approved antiangiogenic drugs in Austria in one of the cancer types defined above.",No,"Biomarker evaluation under antiannagiogenic therapy with Nexavar, Sutent and Avastin. Eligible patients are suffering from hepatocellular carcinoma, non small cell lung cancer, renal cell cancer and colorectal cancer routinely treated with the abov mentioned antiangiogenic agents.",,No,"Histological confirmed Tumor specimen RCC, HCC, CRC or NSCLC",Prior or concurrent antitumor therapy (<3 weeks),Evaluation of biomarker analyses,No,No,No,No,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,Yes,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,Yes,No,No,No,Information not present in EudraCT,Yes,0,2,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,Yes,Yes,No,Yes,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,40,,,Authorised,2009-06-10,2009-06-10,Reason(s) for unfavourable opinion:,Favourable,Completed
2,Rasilez,aliskiren,"['hypertension', 'hypertension']",Germany - BfArM,2008-008287-28,Effect of direct renin-inhibition aliskiren on renal haemodynamic and metabolic parameters in patients with prediabetes,ALI-FRA-0030-I,No,University Hospital Erlangen,Germany,Non-Commercial,Test,Yes,Rasilez 300 mg,Novartis,Germany,No,Rasilez,,,,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,Tablet,No,,2,Patients with prediabetes (either impaired glucose tolerance or imparied fasting glucose) and no obvious diabetes mellitus,No,"The primary aim of this study is to examine the effect of Aliskiren (150mg/daily for 1 week, 300 mg/daily for 4 weeks) on renal hemodynamics in patients with prediabetes and eleveted blood pressure.","The effect of a 5 week lasting therapy with Aliskiren on metabolic parameters (HbA1c, high sensitive CRP, Adiponectin), in patients with impaired glucose tolerance and arterial.",No,Adults aged > 18 to < 70 years,Diabetes Mellitus Type 1/2,"Renal haemodynamic parameters (glomerular filtration rate, renal plasma flow, filtration fraction) under direct renin blockade",Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,Yes,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,No,Yes,No,Yes,No,No,No,No,No,No,Yes,No,No,No,Yes,No,No,No,No,No,,1,No,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,Yes,No,No,No,No,No,No,No,20,,20,Authorised,2010-05-11,,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Zonegran,zonisamide,['nouvellement diagnostiquée traitement appoint traitement crises partielles sans généralisation secondaire chez adultes adolescents enfants âgés'],Sweden - MPA,2005-001982-33,An open label study of Zonegran (zonisamide) in patients with partial onset seizures.,E2090-E044-401,Information not present in EudraCT,Eisai Limited,United Kingdom,Commercial,Test,Information not present in EudraCT,Zonegran 100mg,Eisai Limited,Sweden,No,Zonegran,mg milligram(s),equal,100,Yes,No,No,No,Information not present in EudraCT,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Capsule*,Information not present in EudraCT,Zonisamide,3,"Indicated as adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation.",No,To determine the efficacy and safety of adjunctive open label zonisamide treatment in patients with refractory partial seizures,None stated.,Information not present in EudraCT,1) Male or female adult patients aged 18-75,1) History of status epilepticus within the last 5 years,"The primary endpoint is the change from baseline to end of week 19 in partial seizure frequency. This will allow for a direct comparison of seizure frequency in the fixed dose period (beginning of week 16 to end of week 19) with the baseline seizure frequency, calculated as the average number of seizures/4 week period during 8 consecutive weeks prior to the baseline visit.",No,Information not present in EudraCT,No,No,No,No,No,Yes,Yes,No,No,No,No,No,No,No,No,No,No,Yes,No,No,No,No,No,No,No,No,No,No,No,No,Yes,Yes,No,Information not present in EudraCT,Information not present in EudraCT,12,,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,Yes,Yes,No,Yes,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Information not present in EudraCT,15,1000,1000,Authorised,2006-01-18,2006-03-16,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Zonegran,zonisamide,['nouvellement diagnostiquée traitement appoint traitement crises partielles sans généralisation secondaire chez adultes adolescents enfants âgés'],Denmark - DHMA,2005-001982-33,An open label study of Zonegran (zonisamide) in patients with partial onset seizures.,E2090-E044-401,Information not present in EudraCT,Eisai Limited,United Kingdom,Commercial,Test,Information not present in EudraCT,Zonegran 100mg,Eisai Limited,Denmark,No,Zonegran,mg milligram(s),equal,100,Yes,No,No,No,Information not present in EudraCT,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Capsule*,Information not present in EudraCT,Zonisamide,3,"Indicated as adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation.",No,To determine the efficacy and safety of adjunctive open label zonisamide treatment in patients with refractory partial seizures,None stated.,Information not present in EudraCT,1) Male or female adult patients aged 18-75,1) History of status epilepticus within the last 5 years,"The primary endpoint is the change from baseline to end of week 19 in partial seizure frequency. This will allow for a direct comparison of seizure frequency in the fixed dose period (beginning of week 16 to end of week 19) with the baseline seizure frequency, calculated as the average number of seizures/4 week period during 8 consecutive weeks prior to the baseline visit.",No,Information not present in EudraCT,No,No,No,No,No,Yes,Yes,No,No,No,No,No,No,No,No,No,No,Yes,No,No,No,No,No,No,No,No,No,No,No,No,Yes,Yes,No,Information not present in EudraCT,Information not present in EudraCT,12,,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,Yes,Yes,No,Yes,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Information not present in EudraCT,,1000,1000,Authorised,2006-01-17,2006-03-23,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Zonegran,zonisamide,['nouvellement diagnostiquée traitement appoint traitement crises partielles sans généralisation secondaire chez adultes adolescents enfants âgés'],Finland - Fimea,2005-001982-33,An open label study of Zonegran (zonisamide) in patients with partial onset seizures.,E2090-E044-401,Information not present in EudraCT,Eisai Limited,United Kingdom,Commercial,Test,Information not present in EudraCT,,,,No,Zonegran,mg milligram(s),equal,100,Yes,No,No,No,Information not present in EudraCT,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Capsule*,Information not present in EudraCT,Zonisamide,3,"Indicated as adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation.",No,To determine the efficacy and safety of adjunctive open label zonisamide treatment in patients with refractory partial seizures,None stated.,Information not present in EudraCT,1) Male or female adult patients aged 18-75,1) History of status epilepticus within the last 5 years,"The primary endpoint is the change from baseline to end of week 19 in partial seizure frequency. This will allow for a direct comparison of seizure frequency in the fixed dose period (beginning of week 16 to end of week 19) with the baseline seizure frequency, calculated as the average number of seizures/4 week period during 8 consecutive weeks prior to the baseline visit.",No,Information not present in EudraCT,No,No,No,No,No,Yes,Yes,No,No,No,No,No,No,No,No,No,No,Yes,No,No,Yes,No,No,No,No,No,No,No,No,No,Yes,Yes,No,Information not present in EudraCT,Information not present in EudraCT,12,0,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,Yes,Yes,No,Yes,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Information not present in EudraCT,40,1000,1000,Authorised,2006-08-04,2006-08-08,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Helicobacter Test INFAI,urea (13C),"['infections helicobacter helicobacter', 'infection', 'pylori chez adultes', 'pylori']",Czech Republic - SUKL,2006-000789-35,Two-way Crossover Comparison of the Sensitivity and Specificity of the Modified Helicobacter Test INFAI Using New Test Meal vs. Standard 13C-Urea Breath Test in Helicobacter Pylori Positive and Negative Patients with Dyspepsia Taking Proton Pump Inhibitors,HPTM06/J/05,Information not present in EudraCT,INFAI GmbH,Germany,Commercial,Test,No,Helicobacter Test INFAI,INFAI GmbH,European Union,No,Helicobacter Test INFAI,mg/g milligram(s)/gram,equal,5 to %,Yes,No,No,No,No,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Information not present in EudraCT,Powder for oral solution,Information not present in EudraCT,13C Urea,1,Diagnosis of Helicobacter pylori infection for patients taking proton pump inhibitors (PPI) without interuption of medication two weeks prior to test.,No,To compare the sensitivity of the 13C-UBT test using the new test meal and the standard test meal for Hp in patients with dyspepsia taking PPI,To compare the specificity of the 13C-UBT using the new test meal and the standard test meal for Hp patients with dyspepsia taking PPI,No,- Male and female patients of at least 18 years of age,Previous Hp eradication therapy,"Patients taking PPI, a positive test remains reliable for detection of Hp but the number of false negative tests risesdramatically reducing the sensitivity of these tests. Clinicians are frequently confronted with making a diagnosis of Hp infection in patients who may knowingly be taking PPI. Currently available breath and stool tests are reliable 12-14 days after discontinuation of PPI.",Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,Information not present in EudraCT,No,No,No,Yes,Yes,Yes,No,No,No,No,Yes,No,No,No,No,No,No,Yes,No,Information not present in EudraCT,No,6,,No,No,No,No,No,No,No,Yes,No,Yes,Yes,No,Yes,No,No,No,No,No,No,No,105,115,115,Authorised,2006-10-06,2006-06-28,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Dificlir,fidaxomicin,"['également connues sous nom diarrhée associée difficile madc chez patients adultes pédiatriques pesant moins', 'également connues sous nom diarrhée associée difficile madc chez adultes']",Germany - BfArM,2013-000508-40,"A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or Capsules Taken q6h, for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea",2819-CL-0202,Yes,Astellas Pharma Europe B.V.,Netherlands,Commercial,Comparator,Yes,Vancomycin Capsules 125 MG,Xellia Pharmaceutica ApS,United Kingdom,No,Dificlir,mg milligram(s),equal,125,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,"Capsule, hard",No,VANCOMYCIN HYDROCHLORIDE,4,Treatment of enterocolitis caused by Clostridium difficile,No,The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) aged ≥ 6 months to < 18 years.,"The secondary objectives of this study are to investigate the recurrence/sustained clinical response to and safety of fidaxomicin and vancomycin in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) aged ≥ 6 months to < 18 years, as well as acceptance of the fidaxomicin oral suspension formulation.",No,"1. Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written Informed Consent/ assent ( if applicable) and privacy language as per national regulations (e.g., HIPAA Authorization for U.S. sites) must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).","1. Concurrent use of metronidazole, oral vancomycin or any other antibiotic treatments for CDAD. If the investigator feels the clinical imperative is to begin treatment before knowing the laboratory result for toxigenic C. difficile, up to four doses but no more than 24 hours of treatment with metronidazole, oral vancomycin or any other effective treatment for CDAD are allowed.",Confirmed clinical response based on the assessment by the investigator at EOT+2 days TC/visit,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,No,No,No,No,No,No,No,Yes,No,Yes,Yes,No,Yes,No,Yes,No,No,Yes,No,No,No,Yes,Yes,Yes,No,Yes,8,2,Yes,No,No,No,Yes,Yes,Yes,No,No,Yes,Yes,No,Yes,Yes,Yes,No,No,No,No,No,14,98,144,Authorised,2014-10-24,2014-11-18,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Dificlir,fidaxomicin,"['également connues sous nom diarrhée associée difficile madc chez patients adultes pédiatriques pesant moins', 'également connues sous nom diarrhée associée difficile madc chez adultes']",Belgium - FPS Health-DGM,2013-000508-40,"A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or Capsules Taken q6h, for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea",2819-CL-0202,Yes,Astellas Pharma Europe B.V.,Netherlands,Commercial,Comparator,Yes,Vancomycin Capsules 125 MG,Xellia Pharmaceutica ApS,United Kingdom,No,Dificlir,mg milligram(s),equal,125,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,Capsule,No,VANCOMYCIN HYDROCHLORIDE,4,Treatment of enterocolitis caused by Clostridium difficile,No,The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) from birth to < 18 years of age.,"The secondary objectives of this study are to investigate the recurrence/sustained clinical response to and safety of fidaxomicin and vancomycin in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) from birth to < 18 years of age, as well as acceptance of the fidaxomicin oral suspension formulation.",No,"1. Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written Informed Consent/ assent ( if applicable) and privacy language as per national regulations (e.g., HIPAA Authorization for U.S. sites) must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).","1. Concurrent use of metronidazole, oral vancomycin or any other antibiotic treatments for CDAD. If the investigator feels the clinical imperative is to begin treatment before knowing the laboratory result for toxigenic C. difficile, up to four doses but no more than 24 hours of treatment with metronidazole, oral vancomycin or any other effective treatment for CDAD are allowed.",Confirmed clinical response based on the assessment by the investigator at EOT+2 days TC/visit,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,No,No,No,No,No,No,No,Yes,No,Yes,Yes,No,Yes,No,Yes,No,No,Yes,No,No,No,Yes,Yes,Yes,No,Yes,8,2,Yes,No,No,No,Yes,Yes,Yes,No,No,Yes,Yes,No,Yes,Yes,Yes,No,No,No,No,No,,,144,Authorised,2014-09-03,2014-09-29,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Dificlir,fidaxomicin,"['également connues sous nom diarrhée associée difficile madc chez patients adultes pédiatriques pesant moins', 'également connues sous nom diarrhée associée difficile madc chez adultes']",Slovakia - SIDC (Slovak),2013-000508-40,"A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or Capsules Taken q6h, for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea",2819-CL-0202,Yes,Astellas Pharma Europe B.V.,Netherlands,Commercial,Comparator,Yes,Vancomycin Capsules 125 MG,Xellia Pharmaceutica ApS,United Kingdom,No,Dificlir,mg milligram(s),equal,125,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,Capsule,No,VANCOMYCIN HYDROCHLORIDE,4,Treatment of enterocolitis caused by Clostridium difficile,No,The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) from birth to < 18 years of age.,"The secondary objectives of this study are to investigate the recurrence/sustained clinical response to and safety of fidaxomicin and vancomycin in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) from birth to < 18 years of age, as well as acceptance of the fidaxomicin oral suspension formulation.",No,"1. Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written Informed Consent/ assent ( if applicable) and privacy language as per national regulations (e.g., HIPAA Authorization for U.S. sites) must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).","1. Concurrent use of metronidazole, oral vancomycin or any other antibiotic treatments for CDAD. If the investigator feels the clinical imperative is to begin treatment before knowing the laboratory result for toxigenic C. difficile, up to four doses but no more than 24 hours of treatment with metronidazole, oral vancomycin or any other effective treatment for CDAD are allowed.",Confirmed clinical response based on the assessment by the investigator at EOT+2 days TC/visit,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,No,No,No,No,No,No,No,Yes,No,Yes,Yes,No,Yes,No,Yes,No,No,Yes,No,No,No,Yes,Yes,Yes,No,Yes,5,1,Yes,No,Yes,Yes,Yes,Yes,Yes,No,No,Yes,Yes,No,Yes,Yes,Yes,No,No,No,No,No,4,98,144,Authorised,2014-11-13,2014-09-09,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Dificlir,fidaxomicin,"['également connues sous nom diarrhée associée difficile madc chez patients adultes pédiatriques pesant moins', 'également connues sous nom diarrhée associée difficile madc chez adultes']",Poland - Office for Medicinal Products,2013-000508-40,"A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or Capsules Taken q6h, for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea",2819-CL-0202,Yes,Astellas Pharma Europe B.V.,Netherlands,Commercial,Comparator,Yes,Vancomycin Capsules 125 MG,Xellia Pharmaceutica ApS,United Kingdom,No,Dificlir,mg milligram(s),equal,125,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,"Capsule, hard",No,VANCOMYCIN HYDROCHLORIDE,4,Treatment of enterocolitis caused by Clostridium difficile,No,The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) from birth to < 18 years of age.,"The secondary objectives of this study are to investigate the recurrence/sustained clinical response to and safety of fidaxomicin and vancomycin in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) from birth to < 18 years of age, as well as acceptance of the fidaxomicin oral suspension formulation.",No,"1. Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written Informed Consent/ assent ( if applicable) and privacy language as per national regulations (e.g., HIPAA Authorization for U.S. sites) must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).","1. Concurrent use of metronidazole, oral vancomycin or any other antibiotic treatments for CDAD. If the investigator feels the clinical imperative is to begin treatment before knowing the laboratory result for toxigenic C. difficile, up to four doses but no more than 24 hours of treatment with metronidazole, oral vancomycin or any other effective treatment for CDAD are allowed.",Confirmed clinical response based on the assessment by the investigator at EOT+2 days TC/visit,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,No,No,No,No,No,No,No,Yes,No,Yes,Yes,No,Yes,No,Yes,No,No,Yes,No,No,No,Yes,Yes,Yes,No,Yes,5,4,Yes,No,No,No,Yes,Yes,Yes,No,No,Yes,Yes,No,Yes,Yes,Yes,No,No,No,No,No,12,98,144,Authorised,2014-10-29,,Reason(s) for unfavourable opinion:,,Completed
0,Dificlir,fidaxomicin,"['également connues sous nom diarrhée associée difficile madc chez patients adultes pédiatriques pesant moins', 'également connues sous nom diarrhée associée difficile madc chez adultes']",Italy - Italian Medicines Agency,2013-000508-40,"A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or Capsules Taken q6h, for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea",2819-CL-0202,Yes,Astellas Pharma Europe B.V.,Netherlands,Commercial,Comparator,Yes,Vancomycin Capsules 125 MG,Xellia Pharmaceutica ApS,United Kingdom,No,Dificlir,mg milligram(s),equal,125,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,"Capsule, hard",No,VANCOMYCIN HYDROCHLORIDE,4,Treatment of enterocolitis caused by Clostridium difficile,No,The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) aged ≥ 6 months to < 18 years.,"The secondary objectives of this study are to investigate the recurrence/sustained clinical response to and safety of fidaxomicin and vancomycin in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) aged ≥ 6 months to < 18 years, as well as acceptance of the fidaxomicin oral suspension formulation.",No,"1. Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written Informed Consent/ assent ( if applicable) and privacy language as per national regulations (e.g., HIPAA Authorization for U.S. sites) must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).","1. Concurrent use of metronidazole, oral vancomycin or any other antibiotic treatments for CDAD. If the investigator feels the clinical imperative is to begin treatment before knowing the laboratory result for toxigenic C. difficile, up to four doses but no more than 24 hours of treatment with metronidazole, oral vancomycin or any other effective treatment for CDAD are allowed.",Confirmed clinical response based on the assessment by the investigator at EOT+2 days TC/visit,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,No,No,No,No,No,No,No,Yes,No,Yes,Yes,No,Yes,No,Yes,No,No,Yes,No,No,No,Yes,Yes,Yes,No,Yes,5,1,Yes,No,No,No,Yes,Yes,Yes,No,No,Yes,Yes,No,Yes,Yes,Yes,No,No,No,No,No,8,98,144,Authorised,2014-10-29,2014-12-03,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Dificlir,fidaxomicin,"['également connues sous nom diarrhée associée difficile madc chez patients adultes pédiatriques pesant moins', 'également connues sous nom diarrhée associée difficile madc chez adultes']",Spain - AEMPS,2013-000508-40,"A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or Capsules Taken q6h, for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea",2819-CL-0202,Yes,Astellas Pharma Europe B.V.,Netherlands,Commercial,Comparator,Yes,Vancomycin Capsules 125 MG,Xellia Pharmaceutica ApS,United Kingdom,No,Dificlir,mg milligram(s),equal,125,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,"Capsule, hard",No,VANCOMYCIN HYDROCHLORIDE,4,Treatment of enterocolitis caused by Clostridium difficile,No,The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) aged ? 6 months to < 18 years.,"The secondary objectives of this study are to investigate the recurrence/sustained clinical response to and safety of fidaxomicin and vancomycin in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) aged ? 6 months to < 18 years, as well as acceptance of the fidaxomicin oral suspension formulation.",No,"1. Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written Informed Consent/ assent ( if applicable) and privacy language as per national regulations (e.g., HIPAA Authorization for U.S. sites) must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).","1. Concurrent use of metronidazole, oral vancomycin or any other antibiotic treatments for CDAD. If the investigator feels the clinical imperative is to begin treatment before knowing the laboratory result for toxigenic C. difficile, up to four doses but no more than 24 hours of treatment with metronidazole, oral vancomycin or any other effective treatment for CDAD are allowed.",Confirmed clinical response based on the assessment by the investigator at EOT+2 days TC/visit,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,No,No,No,No,No,No,No,Yes,No,Yes,Yes,No,Yes,No,Yes,No,No,Yes,No,No,No,Yes,Yes,Yes,No,Yes,5,1,Yes,No,No,No,Yes,Yes,Yes,No,No,Yes,Yes,No,Yes,Yes,Yes,No,No,No,No,No,10,98,144,Authorised,2014-12-09,2014-11-14,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Dificlir,fidaxomicin,"['également connues sous nom diarrhée associée difficile madc chez patients adultes pédiatriques pesant moins', 'également connues sous nom diarrhée associée difficile madc chez adultes']",Hungary - National Institute of Pharmacy,2013-000508-40,"A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or Capsules Taken q6h, for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea",2819-CL-0202,Yes,Astellas Pharma Europe B.V.,Netherlands,Commercial,Comparator,Yes,Vancomycin Capsules 125 MG,Xellia Pharmaceutica ApS,United Kingdom,No,Dificlir,mg milligram(s),equal,125,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,Capsule,No,VANCOMYCIN HYDROCHLORIDE,4,Treatment of enterocolitis caused by Clostridium difficile,No,The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) from birth to < 18 years of age.,"The secondary objectives of this study are to investigate the recurrence/sustained clinical response to and safety of fidaxomicin and vancomycin in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) from birth to < 18 years of age, as well as acceptance of the fidaxomicin oral suspension formulation.",No,"1. Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written Informed Consent/ assent ( if applicable) and privacy language as per national regulations (e.g., HIPAA Authorization for U.S. sites) must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).","1. Concurrent use of metronidazole, oral vancomycin or any other antibiotic treatments for CDAD. If the investigator feels the clinical imperative is to begin treatment before knowing the laboratory result for toxigenic C. difficile, up to four doses but no more than 24 hours of treatment with metronidazole, oral vancomycin or any other effective treatment for CDAD are allowed.",Confirmed clinical response based on the assessment by the investigator at EOT+2 days TC/visit,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,No,No,No,No,No,No,No,Yes,No,Yes,Yes,No,Yes,No,Yes,No,No,Yes,No,No,No,Yes,Yes,Yes,No,Yes,8,2,Yes,No,No,No,Yes,Yes,Yes,No,No,Yes,Yes,No,Yes,Yes,Yes,No,No,No,No,No,10,98,144,Authorised,2014-09-30,2014-09-15,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Dificlir,fidaxomicin,"['également connues sous nom diarrhée associée difficile madc chez patients adultes pédiatriques pesant moins', 'également connues sous nom diarrhée associée difficile madc chez adultes']",France - ANSM,2013-000508-40,"A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or Capsules Taken q6h, for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea",2819-CL-0202,Yes,Astellas Pharma Europe B.V.,Netherlands,Commercial,Comparator,Yes,Vancomycin Capsules 125 MG,Xellia Pharmaceutica ApS,United Kingdom,No,Dificlir,mg milligram(s),equal,125,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,"Capsule, hard",No,VANCOMYCIN HYDROCHLORIDE,4,Treatment of enterocolitis caused by Clostridium difficile,No,The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) aged ≥ 6 months to < 18 years.,"The secondary objectives of this study are to investigate the recurrence/sustained clinical response to and safety of fidaxomicin and vancomycin in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) aged ≥ 6 months to < 18 years, as well as acceptance of the fidaxomicin oral suspension formulation.",No,"1. Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written Informed Consent/ assent ( if applicable) and privacy language as per national regulations (e.g., HIPAA Authorization for U.S. sites) must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).","1. Concurrent use of metronidazole, oral vancomycin or any other antibiotic treatments for CDAD. If the investigator feels the clinical imperative is to begin treatment before knowing the laboratory result for toxigenic C. difficile, up to four doses but no more than 24 hours of treatment with metronidazole, oral vancomycin or any other effective treatment for CDAD are allowed.",Confirmed clinical response based on the assessment by the investigator at EOT+2 days TC/visit,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,No,No,No,No,No,No,No,Yes,No,Yes,Yes,No,Yes,No,Yes,No,No,Yes,No,No,No,Yes,Yes,Yes,No,Yes,5,1,Yes,No,No,No,Yes,Yes,Yes,No,No,Yes,Yes,No,Yes,Yes,Yes,No,No,No,No,No,14,98,144,Authorised,2014-10-24,,Reason(s) for unfavourable opinion:,,Completed
1,Cubicin,daptomycin,"['infections', 'infections', 'aureus', 'infections']",Germany - BfArM,2010-022348-18,Application of Daptomycin in MRSA infected diabetic foot  in comparison to vancomycin treatment,MCBC134ADE02T,Information not present in EudraCT,Heart- and Diabetescenter NRW,Germany,Non-Commercial,Test,Yes,Cubicin,Novartis Europharm Limited UK,European Union,No,Cubicin,mg milligram(s),equal,500,Yes,No,No,No,No,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Information not present in EudraCT,Powder for solution for infusion,Information not present in EudraCT,DAPTOMYCIN,4,Patients eligible for this study suffer from diabetic foot infections.,No,Clinical response of the infectionat test-of-cure (TOC) 14 days post therapy,• Duration of therapy,No,•Type 1 and Type 2 Diabetes mellitus,•Osteomyelitis according to international consensus guideline* (3 of 5 criteria apply for diagnosis),Clinical response of the infection at test-of-cure (TOC) 14 days post therapy,No,No,No,No,No,No,Yes,No,Yes,No,No,No,No,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,No,Yes,No,No,Yes,No,No,Yes,No,No,No,Information not present in EudraCT,No,0,3,No,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,No,No,No,No,120,,,Authorised,2010-11-08,2010-09-15,Reason(s) for unfavourable opinion:,Favourable,Prematurely Ended
0,Javlor,vinflunine,['carcinome cellule transitionnelle tumeurs urologiques javlor indiqué monothérapie traitement'],Austria - BASG,2005-001463-64,A Phase II Study of Intravenous (IV) Vinflunine in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium,CA183-001,Information not present in EudraCT,Bristol-Myers Squibb International Corporation,Belgium,Commercial,Test,Information not present in EudraCT,,,,No,Javlor,mg/ml milligram(s)/millilitre,equal,25.0,Yes,No,No,No,No,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Concentrate for solution for infusion,Information not present in EudraCT,Vinflunine Ditartrate,2,"Advanced Cancer, IV, Nos",No,"To estimate the objective response rate (as defined by the WHO criteria modified by the SWOG) in patients with TCC receiving vinflunine, who have had documented",1) To estimate duration of response.,Information not present in EudraCT,1) Provided signed written informed consent.,1) WOCBP who are unwilling or unable to use an acceptable method to avoid,Efficacy:,No,Information not present in EudraCT,Yes,No,Yes,No,No,Yes,Yes,Yes,No,No,No,No,No,No,No,Yes,No,No,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Yes,Yes,Yes,Information not present in EudraCT,Information not present in EudraCT,10,1,No,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,Yes,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,No,5,66,150,Authorised,2005-07-14,2005-07-14,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Javlor,vinflunine,['carcinome cellule transitionnelle tumeurs urologiques javlor indiqué monothérapie traitement'],Spain - AEMPS,2005-001463-64,Estudio en fase II de Vinflunina administrada por vía intravenosa (IV) a pacientes con un carcinoma de células transicionales (CCT) del urotelio localmente avanzado o metastásico.,CA183-001,Information not present in EudraCT,Bristol-Myers Squibb International Corporation,Belgium,Commercial,Test,Information not present in EudraCT,,,,No,Javlor,mg/ml milligram(s)/millilitre,equal,25.0,Yes,No,No,No,No,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Concentrate for solution for infusion,Information not present in EudraCT,Ditartrato de Vinflunina,2,"Cáncer Avanzado, grado IV, Nos",No,"Calcular el índice de respuesta objetiva (definida por los criterios modificados de la OMS) en pacientes con CCT del urotelio que reciban Vinflunina, que hayan tenido una evidencia de progresión documentada en cualquier momento en los 12 meses posteriores a la última dosis de una terapia con platino y no sean candidatos a una cistectomía..",1) Calcular la duración de la respuesta,Information not present in EudraCT,1)El paciente firmará un consentimiento informado por escrito,1)MEF que no quieran o no puedan usar un método anticonceptivo aceptable durante todo el estudio y hasta 12 semanas después de finalizado el mismo.,Eficacia :,No,Information not present in EudraCT,Yes,No,Yes,No,No,Yes,Yes,Yes,No,No,No,No,No,No,No,Yes,No,No,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Yes,Yes,Yes,Information not present in EudraCT,Information not present in EudraCT,10,1,No,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,Yes,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,No,12,66,160,Authorised,2006-01-17,2005-10-11,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Javlor,vinflunine,['carcinome cellule transitionnelle tumeurs urologiques javlor indiqué monothérapie traitement'],Sweden - MPA,2005-001463-64,A Phase II Study of Intravenous (IV) Vinflunine in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium,CA183-001,Information not present in EudraCT,Bristol-Myers Squibb International Corporation,Belgium,Commercial,Test,No,,,,No,Javlor,mg/ml milligram(s)/millilitre,equal,25.0,Yes,No,No,No,No,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Information not present in EudraCT,Concentrate for solution for infusion,Information not present in EudraCT,Vinflunine Ditartrate,2,"Advanced Cancer, IV, Nos",No,"To estimate the objective response rate (as defined by the WHO criteria modified by the SWOG) in patients with TCC receiving vinflunine, who have had documented",1) To estimate duration of response.,No,1) Provided signed written informed consent.,1) WOCBP who are unwilling or unable to use an acceptable method to avoid,Efficacy:,No,No,No,No,No,No,No,Yes,Yes,Yes,No,No,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,Yes,Yes,Yes,Information not present in EudraCT,Yes,10,1,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,No,No,No,No,10,66,150,Authorised,2005-11-02,2005-12-15,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Javlor,vinflunine,['carcinome cellule transitionnelle tumeurs urologiques javlor indiqué monothérapie traitement'],Italy - Italian Medicines Agency,2005-001463-64,A phase II study of intravenous  IV  vinflunine in patients with locally advanced or metastatic transitional cell carcinoma  TCC  of the urothelium.,CA183-001,Information not present in EudraCT,BRISTOL-M.SQUIBB,Italy,Commercial,Test,No,,,,No,Javlor,mg milligram(s),equal,10,Yes,No,No,No,No,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Concentrate for solution for infusion,Information not present in EudraCT,,2,TCC treatment,No,,,Information not present in EudraCT,,,,No,Information not present in EudraCT,Yes,No,Information not present in EudraCT,No,No,Yes,Yes,Yes,No,Information not present in EudraCT,No,No,No,No,No,Yes,No,No,No,No,No,No,No,No,Information not present in EudraCT,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,Yes,Yes,Yes,Information not present in EudraCT,Information not present in EudraCT,,,No,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,Yes,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,No,15,66,160,Authorised,2005-12-16,2005-10-26,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Aranesp,darbepoetin alfa,"['rénale chronique traitement anémie symptomatique associée insuffisance rénale chronique irc chez adultes', 'cancéreux atteints tumeurs malignes']",Denmark - DHMA,2007-007137-38,"En åbent randomiseret fase II undersøgelse af effekten af darbepoietin alfa (Aranesp®) til behandling af anæmi hos patienter med hormonrefraktær prostatacancer, der behandles med Taxotere",48110359,Information not present in EudraCT,Vejle Hospital,Denmark,Non-Commercial,Comparator,Yes,Aranesp,Amgen Europe B.V.,European Union,No,Aranesp,µg/ml microgram(s)/millilitre,equal,500,No,No,No,No,No,Yes,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,Yes,Information not present in EudraCT,Solution for injection,Information not present in EudraCT,,1,Patients with advanced prostate cancer and anaemia,No,"Formålet med dette studie er primært at vurdere effekten af Aranesp® på den hæmatopoietiske reaktion hos patienter med fremskreden prostatacancer og anæmi, der modtager 1.linie kemoterapi. Desuden vurderes effekten af Aranesp® på behov for transfusion med røde blodlegemer. Antal hospitalsindlæggelser og tidsforbruget ved blodtransfusion og Aranesp® behandling vil blive bedømt.","Sekundært vil man vurdere livskvalitet, og om der er en forskel i respons af kemoterapien hos patienter der får Aranesp® sammenlignet med patienter, der ikke får Aranesp®.",No,Inklusionskriterier,"•Kendt primær hæmatologisk lidelse, som kan forårsage anæmi.","1.Hæmoglobinniveau 0, 3, 6, 9, 12, 15, 18 og 21 uger efter starten på darbepoetin alfa. Dosis og varighed af Darbepoetin behandling registreres.",No,No,No,No,Yes,No,Yes,Yes,Yes,No,No,No,Yes,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,No,Yes,Yes,Yes,No,No,Yes,No,No,No,No,Yes,No,Yes,No,No,Information not present in EudraCT,Yes,6,2,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,No,Yes,No,Yes,No,No,No,No,No,No,No,100,,,Authorised,2008-04-07,2008-04-09,Reason(s) for unfavourable opinion:,Favourable,Ongoing
0,Effentora,fentanyl,"['cancer', 'déjà traitement entretien opioïde douleur chronique cancéreuse btp exacerbation transitoire douleur survient contexte douleur persistante autrement contrôlée patients recevant traitement entretien opioïdes ceux prennent moins']",Germany - BfArM,2011-005797-32,"Effentora® for Dyspnoea (EffenDys) - Fentanyl buccal tablet (FBT) for the relief of episodic dyspnoea (ED) in cancer patients: an open label, randomized, morphine-controlled, crossover, phase II trial",Uni-Koeln-1412,No,University of Cologne,Germany,Non-Commercial,Test,Yes,Effentora 600µg,Teva Pharmaceutical Industries Ltd. (TEVA Ltd.) (former Cephalon Inc.),Germany,No,Effentora,µg microgram(s),equal,600,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,Buccal tablet,No,Effentora 600 micrograms buccal tablets,5,Patients with cancer suffering from episodes of dyspnoea (ED),No,To determine the time to onset of meaningful dyspnoea relief of fentanyl buccal tablet (FBT) in comparison to immediate-release morphine (IRM),•	To assess safety of opioids in patients with dyspnoea,No,Principal inclusion criteria:,Principal exclusion criteria:,•	Time to onset of meaningful dyspnoea relief,No,No,No,No,No,No,Yes,Yes,Yes,No,No,No,Yes,No,No,No,No,Yes,No,No,Yes,Yes,Yes,No,No,No,Yes,No,No,No,Yes,No,Yes,No,No,No,Yes,9,1,No,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,Yes,No,No,No,No,No,No,No,30,,,Authorised,2012-11-26,2013-02-28,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Xeloda,capecitabine,"['côlon tumeurs mammaires', 'cancer côlon stade iii stade dukes', 'traitement cancer colorectal', 'traitement patientes atteintes cancer sein localement', 'cancer sein localement avancé métastatique après échec']",UK - MHRA,2004-001926-26,XERXES: Examining the role of early neoadjuvant and synchronous Erbitux in pre-operative chemo-radiotherapy using Xeloda followed by excisional surgery.,XERXES,Information not present in EudraCT,University College London,United Kingdom,Non-Commercial,Test,Information not present in EudraCT,Erbitux,Merck KGaA,,No,Xeloda,,,,Yes,No,No,No,No,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Tablet,Information not present in EudraCT,,2,Locally advanced rectal cancer,No,"To evaluate the safety and toxicity of the combination of erbitux, capecitabine and radiotherapy. This will be determined through an assessment of the patient’s toxicity",To determine the efficacy of the treatment schedules.  This will be determined through an evaluation of disease-free survival.,Information not present in EudraCT,Biopsy proven adenocarcinoma of the rectum (tumour <15cm from anal verge); Indication for pre-operative chemoradiotherapy by virtue of partially fixed/unresectable disease and locally advanced disease (T3/T4) where the preoperative MRI confirms the surgeon is unlikely to perform a R0 resection; WHO performance status 0 or 1; Age ≥18 and fit for surgery.,"Uncontrolled cardiac, respiratory or other disease, or any serious medical or psychiatric disorder that would preclude trial therapy or informed consent; Previous radiotherapy to the pelvis; Previous chemotherapy or radiation for rectal cancer",Acute Toxicity (grade 3 or above in defined Dose Limiting Toxicities),No,Information not present in EudraCT,No,No,No,No,Yes,Yes,Yes,No,No,No,No,No,No,No,No,Yes,No,No,Yes,Yes,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,Yes,No,No,Information not present in EudraCT,No,,3,No,No,No,No,No,No,No,Yes,Yes,Yes,Yes,No,Yes,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,No,48,,48,Authorised,2005-06-10,2005-04-05,Reason(s) for unfavourable opinion:,Favourable,Completed
3,Tygacil,Tigecycline,"['infections bactériennes maladies', 'partir huit ans traitement infections', 'infections', 'infections', 'infections']",Germany - BfArM,2012-005617-39,Pharmacokinetics of Tigecycline in Patients Receiving Continuous Renal Replacement Therapy,WS2030571,No,University Hospital Tuebingen,Germany,Non-Commercial,Test,Yes,Tygacil,Pfizer,European Union,No,Tygacil,mg milligram(s),equal,50,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,Powder for solution for infusion,No,TIGECYCLINE,1,Surgical ICU patients with severe infection and renal replacement therapy,No,"The aim of the present study is to assess the pharmacokinetics of tigecycline in patients with acute renal failure receiving continuous veno-venous hemodialysis (CVVHD) with regional citrate anticoagulation or continuous veno-venous hemodiafiltration (CVVHDF) with conventional heparin-based anticoagulation. Particularly, the following parameters should be evaluated:",Not applicable,No,* Male and female patients,* Pregnant women,AUC of tigecycline during renal replacement therapy in comparison to published pharamkokinetic data in healthy adults,No,No,No,No,No,No,No,No,No,Yes,Yes,No,No,No,No,No,No,No,No,Yes,No,No,Yes,No,No,No,No,No,No,No,No,Yes,No,No,No,No,No,12,,No,No,No,No,No,No,No,Yes,No,Yes,Yes,No,Yes,Yes,Yes,No,No,No,No,No,16,0,0,Authorised,2014-01-14,2013-10-14,Reason(s) for unfavourable opinion:,Favourable,Completed
3,Zeffix,lamivudine,"['compensée signes réplication', 'inflammation', 'hépatique active fibrose instauration traitement']",Germany - BfArM,2005-005987-94,Double-blind placebo-controlled randomised trial of lamivudine in the treatment of acute hepatitis B,GAHB-Study,Information not present in EudraCT,University of Leipzig,Germany,Non-Commercial,Test,Yes,Zeffix,GSK,Germany,No,Zeffix,mg milligram(s),equal,100,Yes,No,No,No,Information not present in EudraCT,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Information not present in EudraCT,"Capsule, hard",Information not present in EudraCT,Lamivudin,1,Acute Hepatitis B,No,- Is time to bilirubin < 2mg/dl shortened by the treatment with lamivudine?,- Is the time to clear HBV-DNA/HBeAg/HBsAg and/or development of anti-HBe/anti-,Yes,- Acute hepatitis,"- Known or obvious pre-existing liver disease (by e.g. spider naevis, ascites)",Time until Bilirubin < 2 mg/dl,No,No,No,Yes,No,No,Yes,Yes,Yes,No,No,No,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,No,Yes,Yes,No,No,Yes,Yes,No,No,No,Yes,No,No,Yes,No,No,Information not present in EudraCT,Yes,,3,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,No,No,No,No,140,,140,Authorised,2006-07-17,2006-06-21,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Naglazyme,galsulfase,"['déficit n-acétylgalactosamine-4-sulfatase syndrome maroteaux-lamy voir rubrique 5 1 comme tous', 'irréversibles maladie', 'traiter']",France - ANSM,2005-003512-30,"A Phase 4 Multi-center, Multi-national, Open-label, Randomized, Two Dose Level Study of Naglazyme (galsulfase) in Infants with Maroteaux-Lamy Syndrome (MPS VI)",ASB-008,Information not present in EudraCT,BioMarin Pharmaceutical Inc.,United States,Commercial,Test,Yes,Naglazyme,BioMarin Europe Ltd.,European Union,Yes,Naglazyme,mg/ml milligram(s)/millilitre,equal,1.0,No,No,No,No,Yes,Yes,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Information not present in EudraCT,Concentrate for solution for infusion,Information not present in EudraCT,galsulfase,1,Mucopolysaccharidosis Type VI (MPS VI; Maroteaux-Lamy Syndrome),Yes,"The primary objective of the study is to evaluate the efficacy of two dose levels of Naglazyme in preventing the progression of skeletal dysplasia in infants under the age of one year who have MPS VI by monitoring physical appearance, x-ray of the skeletal system and growth.","The secondary objective of the study is to evaluate the efficacy of the two dose levels of Naglazyme in preventing several measures of disease progression in infants under the age of one year who have MPS VI by monitoring urinary GAGs, gross and fine motor function, cardiac function, vision, hearing, and use of health resources.",No,"· In the case of subjects under the age of 18, provide written assent (if required) and written informed consent by a parent or legal guardian after the nature of the study has been explained and prior to any research-related procedures;","· Perceived to be unreliable or unavailable for study participation or, if under the age of 18, have parents or legal guardians who are perceived to be unreliable or unavailable;","The primary efficacy endpoint will be assessed by changes in dysmorphic features as assessed by photographs, changes in skeletal dysplasia as assessed by skeletal survey, and growth as measured by height, weight and head circumference. Other potential benefits of treatment will be periodically assessed by evaluation of gross and fine motor skills as part of the Denver II Development Test, cardiac evaluation by echocardiography, complete eye and visual exam, hearing test by audiometry, Health Resource Utilization Questionnaire, and urinary GAGs.",No,No,No,No,No,No,Yes,Yes,Yes,No,No,No,Yes,No,Information not present in EudraCT,No,No,No,No,Yes,No,Yes,Yes,No,No,No,No,No,No,No,No,Yes,No,No,Yes,Information not present in EudraCT,No,0,3,Yes,No,No,Yes,Yes,No,No,No,No,Yes,Yes,No,Yes,Information not present in EudraCT,Information not present in EudraCT,No,No,No,Yes,No,,4,4,Authorised,2007-04-05,2007-03-22,Reason(s) for unfavourable opinion:,Favourable,Completed
0,Kiovig,human normal immunoglobulin (IVIg),"['purpura', 'idiopathique greffe moelle osseuse syndromes déficit immunologique syndrome guillain barre syndrome ganglions lymphatiques cutanéomuqueux thérapie', 'échoué hypogammaglobulinémie infections', 'après', 'infections', 'barré maladie', 'kawasaki neuropathie motrice multifocale']",Germany - PEI,2007-005548-25,"Prospective, randomised (using minimisation), double-blind, placebo controlled study to evaluate the safety and efficacy of human normal immunoglobulin as a prophylactic agent against infections in patients with high grade gliomas",RNOP-12,Information not present in EudraCT,"Freistaat Bayern, vertreten durch Klinikum der Universität Regensburg",Germany,Non-Commercial,Test,Yes,Kiovig,Baxter AG,European Union,No,Kiovig,,,,No,No,No,No,No,Yes,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Yes,No,Information not present in EudraCT,Intravenous infusion,Information not present in EudraCT,,1,"Patients with high-grade gliomas (world health organisation [WHO] grade III or IV) in the first relapse after first-line therapy including chemotherapy with or without nitrososurea, with a life expectancy of at least 6 months and undergoing active treatment with chemotherapy",No,To determine the number of infective episodes in patients with high grade gliomas during treatment with 10% intravenous immunoglobulin (Kiovig) compared with placebo (normal saline).,To determine the following during treatment with Kiovig compared with placebo:,No,1.	Male and female patients ≥ 18 years old,1.	Participation in another clinical trial,The primary endpoint of the study will be the number of infective episodes in patients with high grade glioma during treatment with Kiovig compared with placebo.,No,No,No,Yes,No,No,No,Yes,Yes,No,No,No,No,No,No,No,No,Yes,No,No,Yes,Yes,No,No,Yes,No,No,No,No,Yes,No,Yes,No,No,No,Information not present in EudraCT,No,6,2,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,Yes,Yes,No,Yes,Yes,Yes,No,No,No,No,No,80,,,Authorised,2008-04-30,2008-07-28,Reason(s) for unfavourable opinion:,Favourable,Prematurely Ended
3,Alimta,pemetrexed,"['pleural malin', 'cancer poumon', 'pleural malin', '-cancer poumon petites cellules autre histologie', 'monothérapie traitement entretien cancer poumon', 'cancer poumon']",Germany - BfArM,2006-003816-23,Multicenter phase II study with pemetrexed in patients with pre-treated metastatic soft tissue sarcomas,Alimta,Information not present in EudraCT,Universitätsklinikum Tübingen,Germany,Non-Commercial,Test,Yes,Alimta,Lilly,Germany,No,Alimta,mg/m2 milligram(s)/square meter,equal,500,Yes,No,No,No,No,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Information not present in EudraCT,Powder for infusion*,Information not present in EudraCT,pemetrexed,1,patients with previously treated metastatic soft tissue sarcoma,No,Rate of response,"Determination of the rate of patients who are progression free at 3 and 6 months, changes in median period of survival and progression free survival, determination of toxicity",No,- Histologically confirmed metastasized or locally inoperable soft tissue sarcoma,- Previous or concurrent irradiation of the indicator lesion,,No,No,No,No,No,No,Yes,Yes,Yes,No,No,No,No,No,No,No,No,Yes,No,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,Yes,No,No,Information not present in EudraCT,Yes,6,1,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,No,No,No,No,No,28,,,Authorised,2006-12-13,2006-11-29,Reason(s) for unfavourable opinion:,Favourable,Completed
3,Abilify,aripiprazole,['abilify'],Spain - AEMPS,2005-000472-40,"A Comparative, Randomized, Open -Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who are",CN138-169,Information not present in EudraCT,Bristol-Myers Squibb International Corporation,Belgium,Commercial,Test,Information not present in EudraCT,Abilify,Otsuka Pharmaceutical Europe Ltd.,Spain,No,Abilify,mg milligram(s),equal,15,Yes,No,No,No,No,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Tablet,Information not present in EudraCT,Aripiprazole,3,Schizophrenia,No,To evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing,To investigate whether out of two switching strategies one is best in term of:,Information not present in EudraCT,1) Patients with a diagnosis of schizophrenia as defined by DSM-IV-TR2 criteria,1) WOCBP who are unwilling or unable to use an acceptable method to avoid,Proportion of patients who discontinue due to AE’s.,No,Information not present in EudraCT,No,No,No,No,Yes,Yes,Yes,No,No,No,No,No,No,No,No,No,No,Yes,Yes,Yes,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,No,No,No,Yes,Yes,No,Information not present in EudraCT,Information not present in EudraCT,2,1,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,Yes,Yes,No,Yes,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,No,42,450,450,Authorised,2005-08-10,2005-07-12,Reason(s) for unfavourable opinion:,Favourable,Completed
3,Abilify,aripiprazole,['abilify'],Hungary - National Institute of Pharmacy,2005-000472-40,"A Comparative, Randomized, Open -Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who are",CN 138-169,Information not present in EudraCT,Bristol-Myers Squibb International Corporation,Belgium,Commercial,Test,Information not present in EudraCT,Abilify,Otsuka Pharmaceutical Europe Ltd.,Hungary,No,Abilify,mg milligram(s),equal,15,Yes,No,No,No,No,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Tablet,Information not present in EudraCT,Aripiprazole,3,Schizophrenia,No,To evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing,To investigate whether out of two switching strategies one is best in term of:,Information not present in EudraCT,1) Patients with a diagnosis of schizophrenia as defined by DSM-IV-TR criteria,1) WOCBP who are unwilling or unable to use an acceptable method to avoid,Proportion of patients who discontinue due to AE’s.,No,Information not present in EudraCT,Yes,No,No,No,Yes,Yes,Yes,No,No,No,No,No,No,No,No,No,No,Yes,Yes,Yes,Yes,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Yes,Yes,No,Information not present in EudraCT,Information not present in EudraCT,2,1,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,Yes,Yes,No,Yes,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,No,36,395,450,Authorised,2005-09-28,2005-09-07,Reason(s) for unfavourable opinion:,Favourable,Completed
3,Abilify,aripiprazole,['abilify'],UK - MHRA,2005-000472-40,"A Comparative, Randomized, Open -Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who are",CN 138-169,Information not present in EudraCT,Bristol-Myers Squibb International Corporation,Belgium,Commercial,Test,Yes,Abilify,Otsuka Pharmaceutical Europe Ltd,European Union,No,Abilify,mg milligram(s),equal,15,Yes,No,No,No,No,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Information not present in EudraCT,Tablet,Information not present in EudraCT,Aripiprazole,3,Schizophrenia,No,To evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing,To investigate whether out of two switching strategies one is best in term of:,No,1) Patients with a diagnosis of schizophrenia as defined by DSM-IV-TR criteria,1) WOCBP who are unwilling or unable to use an acceptable method to avoid,Proportion of patients who discontinue due to AE’s.,No,Yes,No,No,No,No,Yes,Yes,Yes,No,No,No,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Yes,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,Yes,Yes,No,Information not present in EudraCT,No,2,1,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,Yes,Yes,No,Yes,Yes,Yes,No,No,No,No,No,25,399,450,Authorised,2005-08-24,2005-10-05,Reason(s) for unfavourable opinion:,Favourable,Completed
3,Abilify,aripiprazole,['abilify'],Austria - BASG,2005-000472-40,"A Comparative, Randomized, Open -Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who are",CN 138-169,Information not present in EudraCT,Bristol-Myers Squibb International Corporation,Belgium,Commercial,Test,Information not present in EudraCT,Abilify,Otsuka Pharmaceutical Europe Ltd.,Austria,No,Abilify,mg milligram(s),equal,15,Yes,No,No,No,No,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Tablet,Information not present in EudraCT,Aripiprazole,3,Schizophrenia,No,To evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing,To investigate whether out of two switching strategies one is best in term of:,Information not present in EudraCT,1) Patients with a diagnosis of schizophrenia as defined by DSM-IV-TR criteria,1) WOCBP who are unwilling or unable to use an acceptable method to avoid,Proportion of patients who discontinue due to AE’s.,No,Information not present in EudraCT,No,No,No,No,Yes,Yes,Yes,No,No,No,No,No,No,No,No,No,No,Yes,Yes,Yes,Yes,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Yes,Yes,No,Information not present in EudraCT,Information not present in EudraCT,2,1,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,Yes,Yes,No,Yes,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,No,18,399,430,Authorised,2005-10-12,2005-10-12,Reason(s) for unfavourable opinion:,Favourable,Completed
3,Abilify,aripiprazole,['abilify'],Germany - BfArM,2005-000472-40,"A Comparative, Randomized, Open -Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who are Experiencing Insufficient Efficacy with Risperidone and/or Safety and Tolerability Issues,While on Risperidone.",CN 138-169,Information not present in EudraCT,Bristol-Myers Squibb International Corporation,Belgium,Commercial,Test,Yes,Abilify,Otsuka Pharmaceutical Europe Ltd,European Union,No,Abilify,mg milligram(s),equal,15,Yes,No,No,No,No,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Information not present in EudraCT,Tablet,Information not present in EudraCT,Aripiprazole,3,Schizophrenia,No,To evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing,To investigate whether out of two switching strategies one is best in term of:,No,1) Patients with a diagnosis of schizophrenia as defined by DSM-IV-TR criteria,1) WOCBP who are unwilling or unable to use an acceptable method to avoid,Proportion of patients who discontinue due to AE’s.,No,No,No,No,No,No,Yes,Yes,Yes,No,No,No,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Yes,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,Yes,Yes,No,Information not present in EudraCT,No,2,1,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,Yes,Yes,No,Yes,Yes,Yes,No,No,No,No,No,42,430,430,Authorised,2005-11-07,2005-12-07,Reason(s) for unfavourable opinion:,Favourable,Completed
3,Abilify,aripiprazole,['abilify'],Czech Republic - SUKL,2005-000472-40,"A Comparative, Randomized, Open -Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who are",CN 138-169,Information not present in EudraCT,Bristol-Myers Squibb International Corporation,Belgium,Commercial,Test,Information not present in EudraCT,Abilify,Otsuka Pharmaceutical Europe Ltd.,Czech Republic,No,Abilify,mg milligram(s),equal,15,Yes,No,No,No,No,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Tablet,Information not present in EudraCT,Aripiprazole,3,Schizophrenia,No,To evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing,To investigate whether out of two switching strategies one is best in term of:,Information not present in EudraCT,1) Patients with a diagnosis of schizophrenia as defined by DSM-IV-TR criteria,1) WOCBP who are unwilling or unable to use an acceptable method to avoid,Proportion of patients who discontinue due to AE’s.,No,Information not present in EudraCT,No,No,No,No,Yes,Yes,Yes,No,No,No,No,No,No,No,No,No,No,Yes,Yes,Yes,Yes,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Yes,Yes,No,Information not present in EudraCT,Information not present in EudraCT,2,1,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,Yes,Yes,No,Yes,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,No,36,399,430,Authorised,2005-10-04,2005-10-12,Reason(s) for unfavourable opinion:,Favourable,Completed
3,Abilify,aripiprazole,['abilify'],Belgium - FPS Health-DGM,2005-000472-40,"A Comparative, Randomized, Open-Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who are",CN 138-169,Information not present in EudraCT,Bristol-Myers Squibb International Corporation,Belgium,Commercial,Test,Information not present in EudraCT,Abilify,Otsuka Pharmaceutical Europe Ltd.,Belgium,No,Abilify,mg milligram(s),equal,15,Yes,No,No,No,No,No,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Tablet,Information not present in EudraCT,Aripiprazole,3,Schizophrenia,No,To evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing,To investigate whether out of two switching strategies one is best in term of:,Information not present in EudraCT,1) Patients with a diagnosis of schizophrenia as defined by DSM-IV-TR criteria,1) WOCBP who are unwilling or unable to use an acceptable method to avoid,Proportion of patients who discontinue due to AE’s.,No,Information not present in EudraCT,Yes,No,No,No,Yes,Yes,Yes,No,No,No,No,No,No,No,No,No,No,Yes,Yes,Yes,Yes,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,Yes,Yes,No,Information not present in EudraCT,Information not present in EudraCT,2,1,No,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Information not present in EudraCT,Yes,No,Yes,Yes,No,Yes,Information not present in EudraCT,Information not present in EudraCT,No,No,No,No,No,36,399,430,Authorised,2005-11-09,2006-09-05,Reason(s) for unfavourable opinion:,Favourable,Completed
3,Baraclude,Entecavir,"['compensée signes réplication', 'inflammation', 'infection']",UK - MHRA,2006-000977-31,"PHASE IIIB, RANDOMIZED, OPEN LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR ENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG POSITIVE CHRONIC HEPATITIS B IN THE IMMUNE TOLERANT PHASE",NV25361,Yes,F. Hoffmann-La Roche Ltd,Switzerland,Commercial,Test,Yes,Baraclude,BRISTOL-MYERS SQUIBB PHARMA EEIG,European Union,No,Baraclude,mg milligram(s),equal,0.5,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,Film-coated tablet,No,ENTECAVIR,5,Chronic Hepatitis B Virus infection,No,"To evaluate the efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.","•To evaluate efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by seroconversion to anti-HBs, seroconversion to anti-HBe, loss of HBeAg, and HBV DNA levels, at 24 weeks post-end of treatment/end of untreated observation.",No,• Male and female patients 3 to less than 18 years of age at baseline (12< 18 years of age at baseline in Russia and India),"Patients who have had any previous anti-HBV treatment, or who are co-infected with hepatitis A virus (HAV), HCV, hepatitis D virus (HDV) or HIV, or who have decompensated liver disease will beexcluded.",Loss of HBsAg at 24 weeks post-end of treatment (follow-up Week 24)/end of untreated observation (Week 80).,No,No,No,No,No,No,Yes,Yes,Yes,Yes,Yes,No,No,No,No,No,No,No,Yes,No,Yes,Yes,Yes,No,No,Yes,No,No,Yes,No,Yes,No,Yes,Yes,Yes,No,Yes,0,7,Yes,No,No,No,No,Yes,Yes,No,No,Yes,Yes,No,Yes,Yes,Yes,No,No,No,Yes,No,10,57,114,Authorised,2006-04-27,2006-05-05,Reason(s) for unfavourable opinion:,Favourable,Completed
3,Baraclude,Entecavir,"['compensée signes réplication', 'inflammation', 'infection']",Belgium - FPS Health-DGM,2006-000977-31,"PHASE IIIB, RANDOMIZED, OPEN LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR ENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG POSITIVE CHRONIC HEPATITIS B IN THE IMMUNE TOLERANT PHASE",NV25361,Yes,F. Hoffmann-La Roche Ltd,Switzerland,Commercial,Test,Yes,Baraclude,BRISTOL-MYERS SQUIBB PHARMA EEIG,European Union,No,Baraclude,mg milligram(s),equal,0.5,Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,Film-coated tablet,No,ENTECAVIR,5,Chronic Hepatitis B Virus infection,No,"To evaluate the efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.","•To evaluate efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by seroconversion to anti-HBs, seroconversion to anti-HBe, loss of HBeAg, and HBV DNA levels, at 24 weeks post-end of treatment/end of untreated observation.",No,• Male and female patients 3 to less than 18 years of age at baseline (12< 18 years of age at baseline in Russia and India),"Patients who have had any previous anti-HBV treatment, or who are co-infected with hepatitis A virus (HAV), HCV, hepatitis D virus (HDV) or HIV, or who have decompensated liver disease will beexcluded.",Loss of HBsAg at 24 weeks post-end of treatment (follow-up Week 24)/end of untreated observation (Week 80).,No,No,No,No,No,No,Yes,Yes,Yes,Yes,Yes,No,No,No,No,No,No,No,Yes,No,Yes,Yes,Yes,No,No,Yes,No,No,Yes,No,Yes,No,Yes,Yes,Yes,No,Yes,0,7,Yes,No,No,No,No,Yes,Yes,No,No,Yes,Yes,No,Yes,Yes,Yes,No,No,No,Yes,No,,57,114,Authorised,2015-10-29,2015-11-02,Reason(s) for unfavourable opinion:,Favourable,Completed
3,Baraclude,Entecavir,"['compensée signes réplication', 'inflammation', 'infection']",Germany - BfArM,2006-000977-31,"PHASE IIIB, RANDOMIZED, OPEN-LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR ENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG-POSITIVE CHRONIC HEPATITIS B IN THE IMMUNE-TOLERANT PHASE",NV25361,No,F. Hoffmann-La Roche Ltd,Switzerland,Commercial,Test,Yes,Baraclude,BRISTOL-MYERS SQUIBB PHARMA EEIG,European Union,No,Baraclude,mg milligram(s),equal,"0,5",Yes,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,No,Film-coated tablet,No,ENTECAVIR,5,Chronic Hepatitis B Virus infection,No,"To evaluate the efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.","•To evaluate efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by seroconversion to anti-HBs, seroconversion to anti-HBe, loss of HBeAg, and HBV DNA levels, at 24 weeks post-end of",No,• Male and female patients 3 to less than 18 years of age at baseline (12 to < 18 years of age at baseline in Russia and India),"Patients who have had any previous anti-HBV treatment, or",Loss of HBsAg at 24 weeks post-end of treatment (follow-up Week 24)/end of untreated observation (Week 80).,No,No,No,No,No,No,Yes,Yes,Yes,Yes,Yes,No,No,No,No,No,No,No,Yes,No,Yes,Yes,Yes,No,No,Yes,No,No,Yes,No,Yes,No,Yes,Yes,Yes,No,Yes,0,7,Yes,No,No,No,No,Yes,Yes,No,No,Yes,Yes,No,Yes,Yes,Yes,No,No,No,Yes,No,10,57,114,Authorised,2014-10-06,2015-01-19,Reason(s) for unfavourable opinion:,Favourable,Completed
